EP4081303A1 - Composition containing cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract, production method thereof, and use of cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract - Google Patents
Composition containing cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract, production method thereof, and use of cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extractInfo
- Publication number
- EP4081303A1 EP4081303A1 EP20906765.1A EP20906765A EP4081303A1 EP 4081303 A1 EP4081303 A1 EP 4081303A1 EP 20906765 A EP20906765 A EP 20906765A EP 4081303 A1 EP4081303 A1 EP 4081303A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cyclo
- composition
- chicken
- salts
- hyp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 143
- 239000000203 mixture Substances 0.000 title claims abstract description 126
- 238000004519 manufacturing process Methods 0.000 title claims description 37
- 150000001413 amino acids Chemical class 0.000 title abstract description 15
- 108010016626 Dipeptides Proteins 0.000 title abstract description 13
- 125000004122 cyclic group Chemical group 0.000 title abstract description 10
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 title abstract description 9
- 239000002212 purine nucleoside Substances 0.000 title abstract description 9
- OWOHLURDBZHNGG-UHFFFAOYSA-N Hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1CNC(=O)C2CCCN12 OWOHLURDBZHNGG-UHFFFAOYSA-N 0.000 claims abstract description 178
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims abstract description 154
- 108010083188 cyclo(prolylglycyl) Proteins 0.000 claims abstract description 88
- 150000003839 salts Chemical class 0.000 claims abstract description 80
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims abstract description 76
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims abstract description 76
- 229940029575 guanosine Drugs 0.000 claims abstract description 76
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 72
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 72
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 18
- 210000000845 cartilage Anatomy 0.000 claims description 68
- 102000000503 Collagen Type II Human genes 0.000 claims description 63
- 108010041390 Collagen Type II Proteins 0.000 claims description 63
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims description 37
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims description 36
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 36
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 35
- 108010087806 Carnosine Proteins 0.000 claims description 35
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 35
- 229940044199 carnosine Drugs 0.000 claims description 35
- 108010085443 Anserine Proteins 0.000 claims description 33
- 241000210053 Potentilla elegans Species 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 25
- 235000013305 food Nutrition 0.000 claims description 24
- 206010061218 Inflammation Diseases 0.000 claims description 21
- 230000004054 inflammatory process Effects 0.000 claims description 21
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 20
- 235000013361 beverage Nutrition 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 102000004889 Interleukin-6 Human genes 0.000 claims description 16
- 108090001005 Interleukin-6 Proteins 0.000 claims description 16
- 229940100601 interleukin-6 Drugs 0.000 claims description 16
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 12
- 102000004890 Interleukin-8 Human genes 0.000 claims description 11
- 108090001007 Interleukin-8 Proteins 0.000 claims description 11
- 108010002335 Interleukin-9 Proteins 0.000 claims description 11
- 102000000585 Interleukin-9 Human genes 0.000 claims description 11
- 229940096397 interleukin-8 Drugs 0.000 claims description 11
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 11
- 229940118526 interleukin-9 Drugs 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims description 6
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims description 6
- 238000002523 gelfiltration Methods 0.000 claims description 6
- 230000004968 inflammatory condition Effects 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 102000000018 Chemokine CCL2 Human genes 0.000 claims 2
- 235000013330 chicken meat Nutrition 0.000 description 133
- 210000004027 cell Anatomy 0.000 description 41
- 239000003480 eluent Substances 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 26
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 23
- 230000002757 inflammatory effect Effects 0.000 description 23
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 238000002203 pretreatment Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 230000002195 synergetic effect Effects 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 210000001612 chondrocyte Anatomy 0.000 description 11
- 238000012549 training Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- 208000006820 Arthralgia Diseases 0.000 description 10
- 102000001326 Chemokine CCL4 Human genes 0.000 description 10
- 108010055165 Chemokine CCL4 Proteins 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- 239000012264 purified product Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 229910021642 ultra pure water Inorganic materials 0.000 description 10
- 239000012498 ultrapure water Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 235000008504 concentrate Nutrition 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 238000005194 fractionation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- -1 inorganic acid salt Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000004365 Protease Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 208000024765 knee pain Diseases 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- OLWOKAYJAHHSNY-QRPNPIFTSA-N (2s)-2-(3-aminopropanoylamino)-3-(3-methylimidazol-4-yl)propanoic acid;nitric acid Chemical compound O[N+]([O-])=O.CN1C=NC=C1C[C@H](NC(=O)CCN)C(O)=O OLWOKAYJAHHSNY-QRPNPIFTSA-N 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000000013 Chemokine CCL3 Human genes 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical class CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000037231 joint health Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 238000007837 multiplex assay Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- OBSLWIKITOYASJ-YDEIVXIUSA-N (3r,4r,5s,6r)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical class CN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OBSLWIKITOYASJ-YDEIVXIUSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- ZHQQRIUYLMXDPP-SSDOTTSWSA-N Actinidine Natural products C1=NC=C(C)C2=C1[C@H](C)CC2 ZHQQRIUYLMXDPP-SSDOTTSWSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- BRMWTNUJHUMWMS-LURJTMIESA-N N(tele)-methyl-L-histidine Chemical compound CN1C=NC(C[C@H](N)C(O)=O)=C1 BRMWTNUJHUMWMS-LURJTMIESA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010043121 Tarsal tunnel syndrome Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- ZHQQRIUYLMXDPP-ZETCQYMHSA-N actinidine Chemical compound C1=NC=C(C)C2=C1[C@@H](C)CC2 ZHQQRIUYLMXDPP-ZETCQYMHSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical group O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940127558 rescue medication Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 210000002517 zygapophyseal joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
- A23L29/281—Proteins, e.g. gelatin or collagen
- A23L29/284—Gelatin; Collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition containing a cyclic dipeptide, a purine nucleoside and/or amino acid, and chicken extract, and a production method thereof.
- the present invention also relates to use of a cyclic dipeptide, a purine nucleoside and/or amino acid, and chicken extract for the production of an anti-inflammatory composition.
- Inflammation is a phenomenon in which histamine, kinins, and the like are released by damaged cells, which causes vasodilation, increased capillary permeability, and aggregation of macrophages at an inflammatory site, resulting in increased blood flow at an infected site, edema, transfer of immune cells and antibodies, pain, fever, or the like.
- NSAID non-steroidal anti-inflammatory drug
- SAID steroidal anti-inflammatory drugs
- Patent Literature 1 discloses an anti-inflammatory composition containing, as an active component, a peptide derived from telomerase having anti-inflammatory activity.
- the present invention aims to provide a novel composition containing a cyclic dipeptide, a purine nucleoside, an amino acid and/or one or more salts thereof, and chicken extract.
- the present invention also aims to provide a composition having an anti-inflammatory action.
- the present inventors found that use of a combination at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract increases anti-inflammatory activity, and completed the present invention.
- the present invention is defined as follows.
- composition according to (1) or (2) above wherein the composition contains a component derived from hydrolyzed collagen type II of chicken cartilage and having a molecular weight of less than 1100 and weight average molecular weight of 150 to 250 as determined by HPLC gel filtration.
- the composition contains hydrolyzed collagen type II of chicken cartilage.
- the chicken extract contains carnosine and/or anserine and/or one or more salts thereof.
- composition according to any one of (1) to (7) above wherein the composition inhibits the production of at least one cytokine selected from the group consisting of regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), and macrophage inflammatory protein-1 (MIP-1).
- RANTES normal T cell expressed and secreted
- MCP-1 monocyte chemotactic protein-1
- IL-6 interleukin-6
- IL-8 interleukin-8
- IL-9 interleukin-9
- MIP-1 macrophage inflammatory protein-1
- a method of producing a composition including mixing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof with chicken extract.
- the mixing includes mixing hydrolyzed collagen type II of chicken cartilage with chicken extract, the hydrolyzed collagen type II containing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof.
- the chicken extract contains carnosine and/or anserine and/or one or more salts thereof.
- the present invention can provide a novel composition containing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract.
- the composition of the present invention can be used as a food or beverage composition or a pharmaceutical composition to reduce inflammation and joint pain.
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, salts thereof, and chicken extract can be consumed as foods, beverages, or the like, and are also advantageous in terms of high safety.
- Fig. 1 is a flow chart summarizing a method of preparing hydrolyzed collagen type II of chicken cartilage.
- Fig. 2 is a group of graphs each showing an effect of fraction P6 on inhibition of the production of inflammatory markers, wherein the fraction P6 is one of among seven fractions obtained in an example by fractionation of hydrolyzed collagen type II (HCII) of chicken cartilage.
- Fig. 3 is a graph showing an effect of HCII, fraction P6 and P6 compounds (a combination of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan) on inhibition of the production of IL-6.
- Fig. 1 is a flow chart summarizing a method of preparing hydrolyzed collagen type II of chicken cartilage.
- Fig. 2 is a group of graphs each showing an effect of fraction P6 on inhibition of the production of inflammatory markers, wherein the fraction P6 is one of among seven fractions obtained in an example by fractionation of hydroly
- Fig. 4 is a graph showing an effect of HCII, fraction P6, P6 compounds (a combination of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan) and Cyclo(Pro-Gly)(cPG) on inhibition of the production of MCP-1.
- Fig. 5 is a graph showing a synergistic effect of a combination of the hydrolyzed collagen type II (HCII) of chicken cartilage and the chicken extract (CE) on inhibition of the production of inflammatory marker MIP-1 ⁇ .
- HCII hydrolyzed collagen type II
- CE chicken extract
- FIGs. 6 (a) and (b) are graphs showing effects of HCII, CE, fraction P6, a synergistic effect of a combination of HCII and CE, and a synergistic effect of a combination of fraction P6 and CE on inhibition of the production of inflammatory markers MCP-1 and MIP-1 ⁇ .
- Figs. 7-1(a) and (b) are graphs showing synergistic effects of a combination of HCII and CE, a combination of P6 compounds and CE, a combination of cPG and CE, a combination of Cyclo (Ala-Hyp)(cAH) and CE, a combination of guanosine and CE, or a combination of tryptophan and CE on inhibition of the production of inflammatory markers IL-6 and IL-8.
- Figs. 7-2(c) and (d) are graphs showing synergistic effects of a combination of HCII and CE, a combination of P6 compounds and CE, a combination of cPG and CE, a combination of cAH and CE, a combination of guanosine and CE, or a combination of tryptophan and CE on inhibition of the production of inflammatory markers IL-9 and MCP-1.
- Figs. 7-2(c) and (d) are graphs showing synergistic effects of a combination of HCII and CE, a combination of P6 compounds and CE, a combination of cPG and CE, a combination of cAH and CE, a combination of guanosine and CE, or a combination of tryptophan and CE on inhibition of the production of inflammatory markers IL-9 and MCP-1.
- Figs. 7-2(c) and (d) are graphs showing synergistic effects of a combination of HCII and CE, a combination of P6 compounds and CE,
- FIG. 7-3(e) and (f) are graphs showing synergistic effects of a combination of HCII and CE, a combination of P6 compounds and CE, a combination of cPG and CE, a combination of cAH and CE, a combination of guanosine and CE, or a combination of tryptophan and CE on inhibition of the production of inflammatory markers MIP-1 ⁇ and RANTES.
- the composition of the present invention contains at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract.
- Cyclo (Ala-Hyp) and Cyclo (Pro-Gly) are cyclic dipeptides.
- cyclic dipeptide refers to a compound containing amino acids as structural units and having a diketopiperazine structure generated by dehydration condensation of an amino group of an amino acid at the N-terminal end and a carboxyl group at the C-terminal end.
- the order of description of amino acids in the cyclic dipeptide is not limited as long as the amino acid composition is the same.
- (Cyclo (Ala-Hyp)) and (Cyclo (Hyp-Ala)) represent the same cyclic dipeptide.
- Guanosine is a purine nucleoside
- tryptophan is an amino acid.
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan may be obtained by hydrolysis of an animal/plant protein or the like, or may be artificially synthesized.
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan are preferably derived from hydrolyzed collagen type II; are more preferably derived from hydrolyzed collagen type II of chicken cartilage; and are still more preferably contained in a fraction derived from hydrolyzed collagen type II of chicken cartilage and having a molecular weight less than 1100 and having weight average molecular weight of 150 to 250 as determined by HPLC gel filtration.
- the "fraction derived from hydrolyzed collagen type II of chicken cartilage and having a molecular weight less than 1100 and having weight average molecular weight of 150 to 250 as determined by HPLC gel filtration" is also referred to as "fraction 6".
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan may be purified before use, may be contained in the form of the fraction 6 containing these components in a composition, or may be contained in the form of hydrolyzed collagen type II of chicken cartilage which contains the fraction 6 in a composition.
- the composition of the present invention contains the fraction 6 or hydrolyzed collagen type II of chicken cartilage.
- the composition of the present invention, which contains the fraction 6 or hydrolyzed collagen type II of chicken cartilage exhibits higher anti-inflammatory action.
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly) and tryptophan can be contained in the form of a salt with an inorganic acid or an organic acid or a salt with an inorganic base or an organic base in the composition of the present invention.
- Such an acid or a base can be selected based on the application of the salt.
- the inorganic acid salt include hydrochloride, nitrate, sulfate, methanesulfonate, and p-toluenesulfonate.
- Examples of the organic acid salt include salts with dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, and salts with monocarboxylic acids such as acetic acid, propionic acid, and butyric acid.
- Examples of the inorganic base include hydroxides, carbonates, and bicarbonates of sodium, lithium, calcium, magnesium, and aluminium and ammonia.
- Examples of the salt with the organic base include mono-, di-, or tri-alkylamine salts such as salts of methylamine, dimethylamine, and triethylamine, mono-, di-, or tri-hydroxyalkylamine salts, guanidine salt, and N-methylglucosamine salt.
- Guanosine can be phosphorylated guanosine in the composition of the present invention.
- the composition of the present invention contains hydrolyzed collagen type II of chicken cartilage.
- Hydrolyzed collagen type II of chicken cartilage (hereinafter, the "hydrolyzed collagen type II of chicken cartilage” is sometimes referred to as "HCII”) can be obtained by hydrolysis of collagen type II with an enzyme or the like.
- the collagen type II can be extracted from chicken cartilage by a known method.
- the hydrolyzed collagen type II of chicken cartilage for use in the present invention can be prepared from cartilage by a method usually used in this field. For example, the hydrolyzed collagen type II can be obtained by treating the chicken cartilage with an enzyme.
- the hydrolyzed collagen type II can be prepared by a pre-treatment step (1) in which chicken cartilage is heated in a liquid, and a step (2) in which the chicken cartilage after the pre-treatment step is treated with an enzyme.
- the enzyme for use in the step (2) is not limited as long as it is one usually used in this field. Examples include collagenase, papain, bromelain, actinidine, ficin, cathepsin, pepsin, chymosin, trypsin, protease, subtilisin, amino peptidase, endopeptidase and exopeptidase and enzyme preparations obtained by mixing these enzymes.
- the method of preparing hydrolyzed collagen type II is not limited to the enzyme treatment method.
- the hydrolyzed collagen type II of chicken cartilage may be a solution obtained by hydrolysis of chicken cartilage, a concentrate or dry powder of the solution, or a purified product of the concentrate or dry powder.
- the purified product of the hydrolyzed collagen type II of chicken cartilage may be obtained by, for example, subjecting a solution obtained by hydrolysis of chicken cartilage to ultrafiltration, membrane treatment, liquid separation operation, or fraction treatment with resin or the like so as to increase the purity.
- the purified product may be formed into powder by freeze-drying or spray-drying, for example.
- Hydrolyzed collagen type II of chicken cartilage is a peptide mixture that usually contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), and/or one or more salts thereof, and can be regarded as a collagen peptide derived from the collagen type II.
- the weight average molecular weight of the hydrolyzed collagen type II of chicken cartilage is preferably 100 to 20,000, more preferably 2,000 to 8,000, still more preferably 3,000 to 7,000.
- the molecular weight and weight average molecular weight can be measured by Eurofins HPAEC-PAD method.
- one fraction or a combination of two or more fractions obtained by fractionation of hydrolyzed collagen type II of chicken cartilage by molecular weight by a method such as gel filtration can be used in the composition of the present invention.
- the fraction obtained by fractionation of hydrolyzed collagen type II of chicken cartilage for use in the composition of the present invention is preferably the fraction 6 described above.
- fraction 6 and a fraction other than fraction 6 may be used in combination in the composition.
- the chicken extract (hereinafter sometimes referred to as "CE") for use in the present invention may be an extract that can be obtained by heating chicken meat used as a raw material in a liquid, or a commercial product.
- the raw material may contain bone, cartilage, legs, or the like, but preferably, the raw material does not contain the head or internal organs.
- Examples of the commercial product of the chicken extract (CE) include “Brand's Essence of Chicken (BEC) (produced by Suntory Beverage & Food Asia Pte Ltd)", “Scotch TM Essence of Chicken (produced by Scotch Industrial (Thailand) Co., Ltd.)", “Quaker Essence of chicken (produced by Standard Foods Corporation (Taiwan) Co., Ltd.)", “Chicken stock and broth of SWANSON TM Produced by Campbell Soup Company (NYSE:CPB)", “Drip Chicken Essence produced by Eu Yan Sang International Ltd. (Singapore)", “Boned Chicken Tonic produced by Eu Yan Sang International Ltd. (Singapore)", “Boiled Essence of Chicken produced by Lao Xie Zhen Co. Ltd. (Taiwan)”. Any of such commercial products may be used, but use of Brand's Essence of Chicken (BEC) is preferred.
- the chicken extract can be produced by a method that is usually used in this field. For example, normal pressure extraction and/or pressurized extraction is performed using a liquid at a temperature of 100°C or higher, preferably 125°C or higher, and the resulting extract is treated with a membrane or filtered, whereby chicken extract can be produced.
- the extract is obtained by a pre-treatment step (3) in which chicken meat is heated in a liquid, and a step (4) in which the liquid is replaced with a fresh liquid after the pre-treatment and the chicken meat is heated again.
- the heat treatment in each of the step (3) and the step (4) is preferably performed in a solvent.
- the solvent is preferably water, ethanol, or a mixture of these, for example.
- the chicken extract encompasses a liquid extract obtained by the method described above; a diluted solution, concentrate, or dry powder of the liquid extract; and purified products of these.
- the purified products may be obtained by, for example, subjecting a chicken extract liquid to ultrafiltration, membrane treatment, liquid separation operation, or fraction treatment with resin or the like so as to increase the purity. After increasing the purity of the chicken extract, the purified product may be formed into powder by freeze-drying or spray-drying, for example.
- the chicken extract for use in the present invention contains carnosine and/or anserine and/or one or more salts thereof.
- Carnosine is ⁇ -alanyl ⁇ histidine, which is a dipeptide of ⁇ -alanine and histidine.
- Anserine is ⁇ -alanyl ⁇ 1-methylhistidine in which histidine is methylated.
- Examples of the carnosine salts and anserine salts include the same salts as those described above for Cyclo (Ala-Hyp), Cyclo (Pro-Gly), and tryptophan.
- the amount of carnosine and/or a salt thereof in the composition is preferably 0.00001 wt% or more, more preferably 0.0001 wt% or more, and is preferably 10 wt% or less, more preferably 1 wt% or less in terms of carnosine.
- the amount of carnosine and/or a salt thereof in the composition is preferably 0.00001 to 10 wt%, more preferably 0.0001 to 1 wt% in terms of carnosine.
- the amount of anserine and/or a salt thereof in the composition is preferably 0.00001 wt% or more, more preferably 0.0001 wt% or more, and also preferably 10 wt% or less, more preferably 1 wt% or less in terms of anserine.
- the amount of anserine and/or a salt thereof in the composition is preferably 0.00001 to 10 wt%, more preferably 0.0001 to 1 wt% in terms of anserine.
- Carnosine, anserine and salts thereof can be quantitated by HPLC, for example. More preferably, the food or beverage composition of the present invention contains carnosine and/or a salt thereof, and anserine and/or a salt thereof.
- the weight ratio of the total weight of the carnosine, anserine and salts thereof in terms of carnosine and anserine to the total weight of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in terms of free form (total of carnosine and anserine/total in terms of free form) is 1/15000 to 200/1.
- the weight ratio is more preferably 1/200 to 200/1, still more preferably 1/50 to 50/1.
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in terms of free from a free form from Cyclo (Ala-Hyp) salt is Cyclo (Ala-Hyp), a free form from Cyclo (Pro-Gly) salt is Cyclo (Pro-Gly), a free form from guanosine salt is guanosine, and a free form from tryptophan salt is tryptophan.
- the weight ratio of the fraction 6 to the total of carnosine, anserine and salts thereof in terms of carnosine and anserine is preferably 1/100 to 10/1.
- the weight ratio is more preferably 1/100 to 5/1.
- the weight ratio of the hydrolyzed collagen type II of chicken cartilage (in terms of solids) to the total of carnosine, anserine and salts thereof in terms of carnosine and anserine is preferably 10000/1 to 10/1.
- the weight ratio is more preferably 1000/1 to 100/1.
- the amount of each component of the composition of the present invention is not limited, and can be set according to the form or the like of the composition.
- the total amount of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in the composition of the present invention is preferably 0.01 wt% or more, more preferably 0.1 wt% or more, and preferably 99 wt% or less, more preferably 90 wt% or less.
- the total amount of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in the composition is preferably 0.01 to 99 wt%, more preferably 0.1 to 90 wt%.
- the amount of fraction 6 in the composition of the present invention is preferably 0.01 wt% or more, more preferably 0.1 wt% or more, and preferably 99 wt% or less, more preferably 90 wt% or less. In an embodiment, for example, the amount of fraction 6 in the composition is preferably 0.01 to 99 wt%, more preferably 0.1 to 90 wt%.
- the amount of fraction 6 contains the amounts of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof.
- the amount of hydrolyzed collagen type II of chicken cartilage (in terms of solids) in the composition of the present invention is preferably 0.1 wt% or more, more preferably 0.5 wt% or more, and preferably 99 wt% or less, more preferably 90 wt% or less.
- the amount of hydrolyzed collagen type II of chicken cartilage (in terms of solids) in the composition is preferably 0.1 to 99 wt%, more preferably 0.5 to 90 wt%.
- the amount of hydrolyzed collagen type II of chicken cartilage contains the amounts of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and fraction 6.
- the amount of chicken extract (in terms of solids) in the composition of the present invention is preferably 0.1 wt% or more, more preferably 0.5 wt% or more, and preferably 99 wt% or less, more preferably 90 wt% or less.
- the amount of chicken extract (in terms of solids) in the composition is preferably 0.1 to 99 wt%, more preferably 0.5 to 90 wt%.
- the amount of chicken extract (in terms of solids) contains the amounts of carnosine and anserine.
- the composition of the present invention is used as a food, beverage, or medicine.
- the food or beverage include general foods or beverages, foods with function claims, health-promoting foods, foods for special dietary uses, dietary supplements, health supplements, and general supplements.
- the form of the food or beverage is not limited. For example, it may be a solid food or a liquid food.
- a beverage is preferred.
- the form of the medicine is not limited. Non-limiting examples include preparations for internal administration such as capsules, tablets, powder, granules, and dry syrups; preparations for external administration such as ointment, adhesive skin patches, eye drops, and suppositories; and injections.
- the medicine is preferably a preparation for internal administration (oral medicine).
- composition of the present invention may contain pharmaceutically or dietary acceptable additives such as various carriers, excipients, diluents, acidulants, antioxidants, stabilizers, preservatives, flavouring or masking agents, emulsifiers, pigments, seasonings, pH adjusters, and nutritional enhancers.
- pharmaceutically or dietary acceptable additives such as various carriers, excipients, diluents, acidulants, antioxidants, stabilizers, preservatives, flavouring or masking agents, emulsifiers, pigments, seasonings, pH adjusters, and nutritional enhancers.
- composition of the present invention is applicable to both therapeutic use (medical use) and non-therapeutic use (non-medical use).
- non-therapeutic is a concept that does not include medical activities, i.e., a concept that does not include methods of surgery, therapy or diagnosis of humans.
- the composition of the present invention can be used to reduce inflammation.
- the composition of the present invention may be an anti-inflammatory composition.
- the composition may be an anti-inflammatory composition containing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract, as active components.
- At least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract are added to a composition, in the same manner as described above for the above composition.
- the hydrolyzed collagen type II of chicken cartilage which contains at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract may be used directly, or a concentrate, dry powder, or purified product thereof may be added as described above, as long as the effect of the present invention is not impaired.
- the same additives as described above can be used.
- the same additives as described above can be used.
- the composition of the present invention is orally fed (orally administered).
- the dose (which can also be described as "intake") of the composition of the present invention is not limited.
- the dose of the composition of the present invention may be suitably set according to the body weight of the subject and the like, as long as the inflammation reducing effect can be achieved.
- the total dose of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in terms of free form is preferably 0.01 mg or more, more preferably 0.1 mg or more, and preferably 2000 mg or less, more preferably 1000 mg or less, per 60 kg body weight per day.
- the total dose of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in terms of free form to a human (adult) is preferably 0.01 to 2000 mg, more preferably 0.1 to 1000 mg, per 60 kg body weight per day.
- the dose of fraction 6 when the composition of the present invention is orally fed or administered to a human (adult), the dose of fraction 6 is preferably 0.01 mg or more, more preferably 0.1 mg or more, and preferably 2000 mg or less, more preferably 1000 mg or less, per 60 kg body weight per day. In an embodiment, the dose of fraction 6 to a human (adult) is preferably 0.01 to 2000 mg, more preferably 0.1 to 1000 mg, per 60 kg body weight per day.
- the dose of fraction 6 contains the amounts of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof.
- the dose of hydrolyzed collagen type II of chicken cartilage is preferably 0.01 mg or more, more preferably 0.1 mg or more, and also preferably 4000 mg or less, more preferably 3000 mg or less, per 60 kg body weight per day.
- the dose of hydrolyzed collagen type II of chicken cartilage (in terms of solids) by a human (adult) is preferably 0.01 to 4000 mg, more preferably 0.1 to 3000 mg, per 60 kg body weight per day.
- the dose of hydrolyzed collagen type II of chicken cartilage contains the amounts of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof or the amount of fraction 6.
- the dose of chicken extract is preferably 0.1 mg or more, more preferably 1 mg or more, and also preferably 15000 mg or less, more preferably 13000 mg or less, per 60 kg body weight per day.
- the dose of chicken extract (in terms of solids) by a human (adult) is preferably 0.1 to 15000 mg, more preferably 1 to 13000 mg, per 60 kg body weight per day.
- the dose of chicken extract includes the amounts of carnosine, anserine and salts thereof.
- the total dose of carnosine, anserine and salts thereof is preferably 0.001 mg or more, more preferably 0.01 mg or more, and also preferably 500 mg or less, more preferably 400 mg or less, per 60 kg body weight per day in terms of carnosine and anserine.
- the total dose of carnosine, anserine and salts thereof fed to a human (adult) is preferably 0.001 to 500 mg, more preferably 0.01 to 400 mg, per 60 kg body weight per day in terms of carnosine and anserine.
- the above amount of hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof and the above amount of chicken extract are preferably fed or administered at least once per day, for example, at once or in several times (e.g., two or three times) per day.
- the above amount of hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof and the above amount of chicken extract are orally fed or administered to a human.
- the composition of the present invention can be used to feed or administer the above amount of hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof and the above amount of chicken extract to a human, per 60 kg body weight per day.
- the composition of the present invention when the composition of the present invention is fed to achieve the anti-inflammatory effect, preferably, the above amount of hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan and/or one or more salts thereof and the above amount of chicken extract are fed.
- the composition of the present invention inhibits the production of cytokines such as regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), and macrophage inflammatory protein-1 (MIP-1).
- cytokines such as regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), and macrophage inflammatory protein-1 (MIP-1).
- MCP-1 interleukin-6
- IL-8 interleukin-8
- IL-9 interleukin-9
- MIP-1 macrophage inflammatory protein-1
- the composition of the present invention can be used to prevent or alleviate inflammatory conditions or diseases.
- the inflammatory conditions or diseases are, for example, conditions or diseases caused by inflammation or conditions or diseases accompanied by inflammation.
- Examples of such conditions or diseases include collagen diseases such as arthritis and rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, tendonitis, sciatica, intervertebral hernia, stenosis, myelopathy, back pain, facet joint pain, carpal tunnel syndrome, tarsal tunnel syndrome, post-lumbar surgery pain syndrome, AIDS, arteriosclerosis, asthma, arthritis, diabetes, hepatitis, stroke, dementia, muscle wasting, viral infection, skin aging including photoaging, cancer, aging, allergic diseases, Parkinson's disease, cerebral infarction, cataract, epilepsy, spinal cord injury, retinopathy of prematurity, nephropathy, peptic ulcer, pancreatitis, ulcerative colitis, myocardial infarction, adult respiratory distress syndrome,
- the composition of the present invention is preferably used to prevent or alleviate these diseases.
- the food or beverage composition is preferably used to prevent or alleviate diseases such as osteoarthritis, heumatoid arthritis and psoriatic arthritis.
- prevention of conditions or diseases encompasses prevention of disease onset, delay of disease onset, reduction in disease incidence, reduction of risk of disease onset, and the like.
- Alleviation of conditions or diseases encompasses recovery of the subject from conditions or diseases, alleviation of conditions or disease symptoms, improvement of conditions or disease symptoms, delay or prevention of progress of conditions or diseases, and the like.
- the subject to which the composition of the present invention is fed or administered (which can also be referred to as a "subject") is not limited.
- the subject is preferably a human or non-human mammal, more preferably a human.
- the subject may be one needing or wanting inhibition of inflammation.
- Such a subject may be, for example, one needing or wanting prevention or alleviation of inflammation or one needing or wanting prevention or alleviation of inflammatory conditions or diseases.
- the subject in the present invention may be a middle-aged or older person.
- the composition of the present invention can also be used by a healthy person, for example, for the purpose of prevention of conditions that can be prevented or alleviated by reducing inflammation.
- composition of the present invention may be labeled with function claims stating that the effect is exerted by reducing inflammation.
- a label is also referred to as a label with function claims, the contents of the label are not limited.
- function claims on the label include "relief of joint pain”, “reduction of joint pain”, “management of knee conditions”, “maintenance of knee health”, “improvement of joint health”, ”improvement of joint mobility” and other function claims equivalent to those mentioned above.
- the composition of the present invention is preferably a food or beverage labeled with the function claims described above, and a beverage is more preferred.
- the label may describe use of the composition of the present invention to achieve the above functions.
- the label may be added to the composition itself or a container or a package of the food or beverage composition.
- the present invention also relates to a method of producing a composition, the method including mixing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, with chicken extract.
- the Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof can be directly mixed with chicken extract.
- a hydrolysate obtained by hydrolysis of collagen type II of chicken cartilage with an enzyme or the like can be directly used for mixing with the chicken extract.
- the fraction 6 derived from hydrolyzed collagen type II of chicken cartilage and containing Cyclo (Ala-Hyp) and the like may be added, or a concentrate, dry powder, or a purified product of hydrolyzed collagen type II of chicken cartilage may be added, as long as the effect of the present invention is not impaired.
- the order of adding raw materials is not limited.
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof, or the fraction 6 or hydrolyzed collagen type II of chicken cartilage which contains these components may be first placed in a container, followed by addition of chicken extract.
- chicken extract may be first placed in a container, followed by addition of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof, or the fraction 6 or hydrolyzed collagen type II of chicken cartilage which contains these components.
- a preferred embodiment of the hydrolyzed collagen type II of chicken cartilage is as described above.
- a preferred embodiment of the chicken extract is as described above.
- the chicken extract contains carnosine and/or anserine and/or one or more salts thereof.
- commercially available chicken extract or chicken extract produced by hot water extraction can be directly mixed with Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof, or the fraction 6 or hydrolyzed collagen type II of chicken cartilage which contains these components.
- the chicken extract when the chicken extract is in the form of a concentrate, dry powder, or a purified product of the concentrate or the dry powder, the chicken extract may be diluted, dissolved, or the like in a liquid such as water, ethanol, or a mixture of water and ethanol, and then mixed with Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof, or the fraction 6 or hydrolyzed collagen type II of chicken cartilage which contains these components, for example.
- a liquid such as water, ethanol, or a mixture of water and ethanol
- the fraction 6 of hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan and/or one or more salts thereof is in the form of a concentrate, dry powder, or a purified product thereof
- a product can be similarly diluted, dissolved, or the like in the liquid or the like before adding.
- such a product may be added without being diluted, dissolved, or the like in advance, and then blended with a liquid so as to be diluted, dissolved, or the like in the liquid.
- composition produced in the production method of the present invention can contain the above-described additives, in addition to Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof as well as hydrolyzed collagen type II of chicken cartilage and chicken extract.
- the present invention also relates to use of at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract for the production of an anti-inflammatory composition.
- the anti-inflammatory composition include a composition similar to the above-described composition containing Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof, and chicken extract.
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof can be used in the form of the fraction 6 or hydrolyzed collagen type II of chicken cartilage which contains these components.
- the same chicken extract and the same additives as described above can be used.
- Fig. 1 shows a flow chart briefly describing a HCII preparation method.
- frozen chicken cartilage was thawed in water at 40°C, and cleansed in water at 40°C (1 hour).
- the wash water was discarded, and fresh water was poured into a 1200L pot as to be 3 times amount to the chicken cartilage.
- the water was heated to the optimal working temperature for enzyme treatment, and the washed chicken cartilage was immersed therein to perform enzyme treatment for several hours.
- the pot containing the chicken cartilage was heated to 90°C or higher, and the temperature was held at 90°C or higher for 30 minutes, whereby the enzyme used in the earlier enzyme treatment was inactivated.
- the resulting mixture (the liquid and the enzyme-treated chicken cartilage) was filtered.
- the resulting liquid was concentrated.
- the resulting concentrate was spray-dried at 200°C, whereby HCII powder was prepared.
- Fractions were collected every 0.5 min between 8 min to 28 min using a GX series fraction collector (Gilson), the resulted 40 individual fractions were subsequently pooled into 7 fractions, P1 to P7 (P1: 8.5-12.0 min, P2: 12.0-13.5 min, P3: 13.5-14.5 min, P4: 14.5-16.0 min, P5: 16.0-17.5 min, P6: 17.5-19.0 min, P7: 19.0-27.5 min).
- the pooled fractions were evaporated to dryness in a freeze dryer (ScanVac) and the dried samples were stored at -20°C until further use.
- ScanVac freeze dryer
- Table 2 shows the molecular weights of the fractions obtained above.
- Mw and “Mp” indicate weight average molecular weight and peak molecular weight, respectively.
- fraction 6 was composed of general small molecules having a molecular weight of less than 300.
- the molecular weights of fractions of HCII were measured by HPLC Gel filtration method under the following conditions. Instrument: Agilent 1100 Series Detection: UV 214 nm Flow rate: 1mL/min Mobile phase: Isocratic 0.1 mM Sodium phosphate buffer at pH 6.8 Running time: 20 minutes
- the injection volume was 10 ⁇ L at the flow rate of 1 mL/min and UV absorbance of the eluents was monitored at 214 nm.
- the eluates were collected with equipped fraction collector.
- Four fractions were then freeze-dried and then reconstituted in purified water, which submitted to LC-MS analysis on an Agilent HPLC 1290 series-coupled TripleTOF 5600 (AB Sciex) with a Duo Spray Turbo V ion source and a gas generator (Peak Scientific).
- Some fractions were also submitted to proton-NMR experiment, conducted on Bruker ECA 400 for characterization.
- the identity of the major components in the fraction P6 was confirmed by commercially available chemicals. Free amino acids in the fraction HCII were detected and quantified according to AOAC 999.13 method.
- the major components in the fraction P6 were Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan.
- the injection volume was 10 ⁇ L at the flow rate of 300 ⁇ L/min and UV absorbance of the eluents was monitored at 214 nm.
- the collision energy (CE) and declustering potential (DP) of the MS were optimized as 27.0 V and 100 V respectively.
- Cyclo (Ala-Hyp) was detected using Q1/Q3 ion transitions at m/z 185.1/86.1 with the retention time of 2.45 min as quantifier and qualifier.
- a calibration curve was constructed by infusing 31.25 ng/mL, 62.5 ng/mL, 125 ng/mL, or 250 ng/mL of standard Cyclo (Ala-Hyp) into the mass spectrometer.
- the fraction P6 was reconstituted as 100 ⁇ g/mL solution as the working solution.
- the quantification of the Cyclo (Ala-Hyp) in the fraction P6 was done by Sciex OS (AB Sciex).
- the injection volume was 10 ⁇ L at the flow rate of 300 ⁇ L/min and UV absorbance of the eluents was monitored at 214 nm.
- the collision energy (CE) and declustering potential (DP) of the MS were optimized as 30.0 V and 100 V respectively.
- Cyclo (Pro-Gly) was detected using Q1/Q3 ion transitions at m/z 70.1/127.1 Th with the retention time of 2.6 min as quantifier and qualifier.
- a calibration curve was constructed by infusing 70 ng/mL, 140 ng/mL, 280 ng/mL, or 560 ng/mL of standard Cyclo (Pro-Gly) into the mass spectrometer.
- the fraction P6 was reconstituted as 100 ⁇ g/mL solution as the working solution.
- the quantification of the Cyclo (Pro-Gly) in the fraction P6 was done by Sciex OS (AB Sciex).
- the injection volume was 10 ⁇ L at the flow rate of 300 ⁇ L/min and UV absorbance of the eluents was monitored at 214 nm.
- the collision energy (CE) and declustering potential (DP) of the MS were optimized as 10.0 V and 80 V respectively.
- Guanosine was detected using Q1/Q3 ion transitions at m/z152.1/284.1Th with the retention time of 2.17 min as quantifier and qualifier.
- a calibration curve was constructed by infusing 31.25 ng/mL, 62.5 ng/mL, 125 ng/mL, or 250 ng/mL of standard guanosine into the mass spectrometer.
- P6 was reconstituted as 100 ⁇ g/mL solution as the working solution.
- the quantification of the guanosine in P6 was done by Sciex OS (AB Sciex).
- HCII contained 0.23wt% of Cyclo (Ala-Hyp), 0.30wt% of Cyclo (Pro-Gly), 0.10wt% of guanosine, and 0.132wt% of tryptophan, assuming the total weight of the HCII as 100 wt%.
- Carnosine standard stock was prepared by adding and dissolving carnosine powder in deionized water to a carnosine concentration of 2.50 mg/ml.
- Anserine standard stock was prepared by adding and dissolving L-anserine nitrate powder in deionized water to an L-anserine concentration of 3.96 mg/ml.
- the weight of L-anserine was calculated by the following formula.
- L-anserine (g) 0.792 ⁇ L-anserine nitrate (g) ⁇ Analysis conditions of HPLC>
- Device High performance liquid chromatography system with UV detector (Agilent 1100 produced by Agilent). Column: Zorbax 300-SCX 4.6 mm ID ⁇ 250 mm (Agilent)
- Mobile phase 50 mM potassium dihydrogen phosphate
- Flow rate 1.0 mL/min
- UV detector wavelength 210 nm
- Sample injection volume 10 ⁇ L
- Example and Comparative Examples the effect of inhibiting the production of inflammatory markers was evaluated by the following method.
- Chicken extract (CE) Brand's Essence of Chicken (Suntory Beverage & Food Asia Pte Ltd, carnosine content in 1 ml: 0.94 mg/ml; anserine content in 1 ml: 1.9 mg/ml)) Chondrocyte medium (CM), fetal bovine serum (FBS), chondrocyte growth supplement (CGS), and penicillin/streptomycin (P/S): ScienCell Research Laboratories IL-1 ⁇ : R&D Systems Poly-L-lysine (PLL) coated 96-well plates (Corning)
- chondrocytes (HC-a, ScienCell Research Laboratories) were isolated from human articular cartilage and were maintained in CM supplemented with 5% FBS, 1% CGS and 1% P/S. Cells were seeded in PLL-coated 96-well plate at a cell density of 4000 cells/well and incubated overnight at 37°C in a humidified gas chamber containing 5% CO 2 .
- the chondrocytes were washed once with PBS, and treated with chicken extract (CE), HCII, fraction P6 fractionated from HCII, a combination of the fraction P6 and CE, P6 compounds containing Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan, a combination of P6 compounds and CE, Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, or a combination of CE and any one of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine or tryptophan.
- CE chicken extract
- chondrocytes were further treated for 24 hours by adding 25 ng/m of IL-1 ⁇ .
- the cells were centrifuged at 1100 g for 5 minutes and the supernatant was then used for cytokine analysis.
- cells treated with IL-1 ⁇ without being pre-treated with CE, HCII, fraction P6, P6 compounds, Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan were prepared.
- IL-1 ⁇ The Pro-Human Cytokine Multiplex Assays (Bio-Rad) was used to analyze the cytokines in the culture media. The following 27-plex analyses were performed: IL-1 ⁇ , IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, eotaxin (CCL11), macrophage colony-stimulating factor (M-CSF), interferon (IFN)- ⁇ , monocyte chemotactic protein 1 (MCP-1; CCL2), macrophage inflammatory protein-1 ⁇ (MIP-1 ⁇ ; CCL3), MIP-1 ⁇ (CCL4), regulated on activation, normal T cell expressed and secreted (RANTES) (CCL5), TNF- ⁇ , and vascular endothelial growth factor (VEGF).
- MCP-1 monocyte chemotactic protein 1
- MIP-1 ⁇ macrophage inflammatory
- the HCII concentration was 5 mg/ml
- the fraction P6 concentration was 5 mg/ml.
- IL-1 ⁇ 25 ng/mL induced inflammation in human chondrocytes leading to a significant increase in level of all the inflammatory markers as compared to untreated cells (control).
- Pre-treatment of the cells with HCII or the fraction P6 reduced the level of all the inflammatory markers induced by IL-1 ⁇ .
- HCII-treated cells, fraction P6-treated cells and P6 compounds-treated cells were pre-treated with HCII, fraction P6 or P6 compounds.
- the HCII concentration was 5 mg/ml
- the fraction P6 concentration was 5 mg/ml
- the P6 compounds concentration was 100 mg/ml.
- IL-1 ⁇ 25 ng/mL induced inflammation in human chondrocytes leading to a significant increase in level of IL-6 as compared to untreated cells (control).
- Pre-treatment of the cells with HCII, P6, or P6 compounds reduced the level of the inflammatory marker IL-6 induced by IL-1 ⁇ .
- HCII-treated cells, fraction P6-treated cells, P6 compounds-treated cells and cPG-treated cells were pre-treated with HCII, fraction P6, P6 compounds or cPG.
- the HCII concentration was 5 mg/ml
- the fraction P6 concentration was 5 mg/ml
- the P6 compounds concentration was 100 mg/ml
- the cPG concentration was 50 mg/ml, 100 mg/ml or 250 mg/ml.
- IL-1 ⁇ 25 ng/mL induced inflammation in human chondrocytes leading to a significant increase in level of MCP-1(MCAF) as compared to untreated cells (control).
- Example 1 Synergistic effect of combination of HCII and CE
- HCII concentration was 0.5 mg/ml
- CE concentration was 1.25 mg/ml
- a combination of HCII 0.5 mg/mL and CE 1.25 mg/mL provided a synergistic effect of reducing inflammation, as compared to treatment with HCII or CE alone.
- Example 2 Synergistic effect of combination of HCII and CE and a synergistic effect of a combination of fraction P6 and CE on inhibition of the production of inflammatory markers MCP-1 and MIP-1 ⁇
- pre-treatment was performed with IL-1 ⁇ and HCII alone, CE alone, P6 alone, a combination of HCII and CE, or a combination of P6 and CE as in Example 1.
- HCII concentration was 2.5mg/mL or 5mg/mL
- P6 concentration was 2.5 mg/ml or 5mg/mL
- CE concentration was 6.25 mg/ml.
- Example 3 Synergistic effect of combination of HCII and CE, a combination of P6 compound and CE, a combination of Cyclo(Pro-Gly) and CE, a combination of Cyclo (Ala-Hyp) and CE, a combination of guanosine and CE, and a combination of tryptophan and CE on inhibition of the production of inflammatory markers
- HCII concentration was 2.5mg/mL
- P6 compounds concentration was 25 mg/ml, 125 mg/ml or 250mg/mL
- cPG concentration was 25 mg/ml, 125 mg/ml or 250mg/mL
- cAH concentration was 25 mg/ml, 125 mg/ml or 250mg/mL
- guanosine concentration was 25 mg/ml
- tryptophan concentration was 25 mg/ml, 125 mg/ml or 250mg/mL
- CE concentration was 6.25 mg/ml.
- Example 4 A Randomized, Double-blind, Four-arm Pilot Study to Evaluate the Effects of HCII and CE on knee pain This pilot study was carried out in a single-center, and as double-blind, randomized, placebo-controlled study.
- Subject enrolment and randomization A total of 160 subjects between the ages of 45 to 75 were selected using inclusion and exclusion criteria summarized in Table 3. Subjects were randomly assigned to four groups i.e. “Placebo”, “Glucosamine”, “HCII” and “HCII and CE”. Each group included 40 subjects.
- HCII Collagen Hydrolysate (Suntory Beverage & Food Asia Pte Ltd), a hydrolyzed chicken sternal cartilage extract composed of a naturally occurring matrix of hydrolyzed collagen type II (HCII) and low molecular weight chondroitin sulfate and hyaluronic acid (HA).
- HCII HCII containing Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine and tryptophan.
- Each bottle with a volume of 68mL contained 2g of HCII providing naturally occurring composition of HCII (66.5%), depolymerized chondroitin sulfate (18%) and HA (11%).
- Uncharacterized components of sternal cartilage account for the remaining 4.5%.
- “HCII and CE” group took a mixture of 70g of BRAND’S Essence of chicken (BEC) (dry weight: 5-6g) and 2g of HCII in 68mL.All test products were prepared as liquid products in glass bottles, which were isocaloric, identical in appearance and equivalent in flavour and texture.
- PDC Proportion of days covered (PDC) of painkillers was calculated based on the records in the Concomitant Medication of Painkiller section and defined as the percentage of painkillers covered days over the total number of days in the interval between visits.
- Any treatment or dietary supplement that could support joint, bone and muscle health including hormone therapy (growth hormone, progesterone, estrogen, or testosterone), calcium and vitamin D, supplements enriched with amino acids, peptides, proteins, omega-3, omega-6, glucosamine or chondroitin were prohibited throughout the study duration.
- the study consisted of a screening visit (28 days before baseline visit), followed by a baseline visit (Baseline visit was Day 0. Screening and baseline visits can be on the same day), and 3 follow-up visits (Week 8, 16, and 24). Subjects were screened from Day -28 to Day 0 to determine the eligibility for the study. Intake of test product was taken starting from the day following the baseline visit for 168 days (24 weeks) consecutively. For 168 days (24 weeks) consecutively, subjects took one bottle of test product daily in the morning (after meal). Intake compliance was recorded on a diary card. The visual analogue scale (VAS) of knee pain was scored at Day 0, Day 7 and Day 14 post-intake. During the study period, subjects were recommended to do the resistance training (not mandatory) twice a week at home, 30 minutes each time following the training schedule. Training was recorded on a diary card. Food dietary in the prior week before visits was recorded using a food questionnaire.
- VAS visual analogue scale
- a compliance rate of ⁇ 50% was considered as compliant.
- VAS Visual Analogue scale
- HCII and CE were well-tolerated and provided a quick and significant symptomatic relief in patients suffering from osteoarthritic pain. Compared to placebo, combination of HCII and CE significantly reduced knee joint pain in just 14 days in subjects who did minimal amount of resistance training. In vitro studies suggest that mechanism of action may be through modification of underlying disease processes, particularly inhibition of inflammation that leads to localized pain sensation. Taken together, a combination of HCII and CE may be considered as a safe and efficacious complement to current medical and dietary options in the management of OA symptoms.
- the present invention can provide a novel composition containing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract.
- the composition of the present invention can be used as a food or beverage composition or a pharmaceutical composition to reduce inflammation and joint pain.
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, salts thereof, and chicken extract can be consumed as foods, beverages, or the like, and are also advantageous in terms of high safety.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
- The present invention relates to a composition containing a cyclic dipeptide, a purine nucleoside and/or amino acid, and chicken extract, and a production method thereof. The present invention also relates to use of a cyclic dipeptide, a purine nucleoside and/or amino acid, and chicken extract for the production of an anti-inflammatory composition.
- Inflammation is a phenomenon in which histamine, kinins, and the like are released by damaged cells, which causes vasodilation, increased capillary permeability, and aggregation of macrophages at an inflammatory site, resulting in increased blood flow at an infected site, edema, transfer of immune cells and antibodies, pain, fever, or the like.
- Recently, components capable of inhibiting expression of a protein related to inflammation have been studied to provide effective relief of inflammation. While anti-inflammatory drugs having various mechanisms, such as non-steroidal anti-inflammatory drug (NSAID) and steroidal anti-inflammatory drugs (SAID), have been developed, these drugs may have side effects. Thus, there is still a demand for components that are safer and that have anti-inflammatory action.
- For example, Patent Literature 1 discloses an anti-inflammatory composition containing, as an active component, a peptide derived from telomerase having anti-inflammatory activity.
-
JP2015-525768T - The present invention aims to provide a novel composition containing a cyclic dipeptide, a purine nucleoside, an amino acid and/or one or more salts thereof, and chicken extract.
The present invention also aims to provide a composition having an anti-inflammatory action. - The present inventors found that use of a combination at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract increases anti-inflammatory activity, and completed the present invention.
- Specifically, the present invention is defined as follows.
(1) A composition containing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract.
(2) The composition according to (1) above, wherein the total amount of the at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof is 0.01 to 99 wt%.
(3) The composition according to (1) or (2) above, wherein the composition contains a component derived from hydrolyzed collagen type II of chicken cartilage and having a molecular weight of less than 1100 and weight average molecular weight of 150 to 250 as determined by HPLC gel filtration.
(4) The composition according to any one of (1) to (3) above, wherein the composition contains hydrolyzed collagen type II of chicken cartilage.
(5) The composition according to any one of (1) to (4) above, wherein the chicken extract contains carnosine and/or anserine and/or one or more salts thereof.
(6) The composition according to any one of (1) to (5) above, wherein the composition is a food, beverage, or medicine.
(7) The composition according to any one of (1) to (6) above, wherein the composition is used to reduce inflammation.
(8) The composition according to any one of (1) to (7) above, wherein the composition inhibits the production of at least one cytokine selected from the group consisting of regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), and macrophage inflammatory protein-1 (MIP-1).
(9) The composition according to any one of (1) to (8) above, wherein the composition is used to prevent or alleviate inflammatory conditions or diseases.
(10) A method of producing a composition, including mixing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof with chicken extract.
(11) The production method according to (10) above, wherein the mixing includes mixing hydrolyzed collagen type II of chicken cartilage with chicken extract, the hydrolyzed collagen type II containing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof.
(12) The production method according to (10) or (11) above, wherein the chicken extract contains carnosine and/or anserine and/or one or more salts thereof.
(13) Use of at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract for the production of an anti-inflammatory composition. - The present invention can provide a novel composition containing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract. The composition of the present invention can be used as a food or beverage composition or a pharmaceutical composition to reduce inflammation and joint pain. Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, salts thereof, and chicken extract can be consumed as foods, beverages, or the like, and are also advantageous in terms of high safety.
-
Fig. 1 is a flow chart summarizing a method of preparing hydrolyzed collagen type II of chicken cartilage. Fig. 2 is a group of graphs each showing an effect of fraction P6 on inhibition of the production of inflammatory markers, wherein the fraction P6 is one of among seven fractions obtained in an example by fractionation of hydrolyzed collagen type II (HCII) of chicken cartilage. Fig. 3 is a graph showing an effect of HCII, fraction P6 and P6 compounds (a combination of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan) on inhibition of the production of IL-6. Fig. 4 is a graph showing an effect of HCII, fraction P6, P6 compounds (a combination of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan) and Cyclo(Pro-Gly)(cPG) on inhibition of the production of MCP-1. Fig. 5 is a graph showing a synergistic effect of a combination of the hydrolyzed collagen type II (HCII) of chicken cartilage and the chicken extract (CE) on inhibition of the production of inflammatory marker MIP-1β. Figs. 6 (a) and (b) are graphs showing effects of HCII, CE, fraction P6, a synergistic effect of a combination of HCII and CE, and a synergistic effect of a combination of fraction P6 and CE on inhibition of the production of inflammatory markers MCP-1 and MIP-1β. Figs. 7-1(a) and (b) are graphs showing synergistic effects of a combination of HCII and CE, a combination of P6 compounds and CE, a combination of cPG and CE, a combination of Cyclo (Ala-Hyp)(cAH) and CE, a combination of guanosine and CE, or a combination of tryptophan and CE on inhibition of the production of inflammatory markers IL-6 and IL-8. Figs. 7-2(c) and (d) are graphs showing synergistic effects of a combination of HCII and CE, a combination of P6 compounds and CE, a combination of cPG and CE, a combination of cAH and CE, a combination of guanosine and CE, or a combination of tryptophan and CE on inhibition of the production of inflammatory markers IL-9 and MCP-1. Figs. 7-3(e) and (f) are graphs showing synergistic effects of a combination of HCII and CE, a combination of P6 compounds and CE, a combination of cPG and CE, a combination of cAH and CE, a combination of guanosine and CE, or a combination of tryptophan and CE on inhibition of the production of inflammatory markers MIP-1β and RANTES. Fig. 8 is a graph showing an effect of 14-day intake with hydrolyzed collagen type II of chicken cartilage (HCII) and a combination of HCII and chicken extract (CE) on VAS pain score on Days 7 and 14 in each treatment group for subjects doing less than 10th percentile of total resistance training period (n=8). - In an embodiment of the present invention, the composition of the present invention contains at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract.
- Cyclo (Ala-Hyp) and Cyclo (Pro-Gly) are cyclic dipeptides. Herein, the term "cyclic dipeptide" refers to a compound containing amino acids as structural units and having a diketopiperazine structure generated by dehydration condensation of an amino group of an amino acid at the N-terminal end and a carboxyl group at the C-terminal end. Herein, the order of description of amino acids in the cyclic dipeptide is not limited as long as the amino acid composition is the same. For example, (Cyclo (Ala-Hyp)) and (Cyclo (Hyp-Ala)) represent the same cyclic dipeptide.
Guanosine is a purine nucleoside, and tryptophan is an amino acid. - Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan may be obtained by hydrolysis of an animal/plant protein or the like, or may be artificially synthesized. Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan are preferably derived from hydrolyzed collagen type II; are more preferably derived from hydrolyzed collagen type II of chicken cartilage; and are still more preferably contained in a fraction derived from hydrolyzed collagen type II of chicken cartilage and having a molecular weight less than 1100 and having weight average molecular weight of 150 to 250 as determined by HPLC gel filtration. Herein, the "fraction derived from hydrolyzed collagen type II of chicken cartilage and having a molecular weight less than 1100 and having weight average molecular weight of 150 to 250 as determined by HPLC gel filtration" is also referred to as "fraction 6".
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan may be purified before use, may be contained in the form of the fraction 6 containing these components in a composition, or may be contained in the form of hydrolyzed collagen type II of chicken cartilage which contains the fraction 6 in a composition. In a preferred embodiment, the composition of the present invention contains the fraction 6 or hydrolyzed collagen type II of chicken cartilage. The composition of the present invention, which contains the fraction 6 or hydrolyzed collagen type II of chicken cartilage, exhibits higher anti-inflammatory action.
- Cyclo (Ala-Hyp), Cyclo (Pro-Gly) and tryptophan can be contained in the form of a salt with an inorganic acid or an organic acid or a salt with an inorganic base or an organic base in the composition of the present invention. Such an acid or a base can be selected based on the application of the salt. In view of application to foods, beverages, and medicines, the following dietary or pharmaceutically acceptable salts are preferred. Examples of the inorganic acid salt include hydrochloride, nitrate, sulfate, methanesulfonate, and p-toluenesulfonate. Examples of the organic acid salt include salts with dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, and salts with monocarboxylic acids such as acetic acid, propionic acid, and butyric acid. Examples of the inorganic base include hydroxides, carbonates, and bicarbonates of sodium, lithium, calcium, magnesium, and aluminium and ammonia. Examples of the salt with the organic base include mono-, di-, or tri-alkylamine salts such as salts of methylamine, dimethylamine, and triethylamine, mono-, di-, or tri-hydroxyalkylamine salts, guanidine salt, and N-methylglucosamine salt.
Guanosine can be phosphorylated guanosine in the composition of the present invention. - <Hydrolyzed collagen type II of chicken cartilage>
Preferably, the composition of the present invention contains hydrolyzed collagen type II of chicken cartilage.
Hydrolyzed collagen type II of chicken cartilage (hereinafter, the "hydrolyzed collagen type II of chicken cartilage" is sometimes referred to as "HCII") can be obtained by hydrolysis of collagen type II with an enzyme or the like. The collagen type II can be extracted from chicken cartilage by a known method. The hydrolyzed collagen type II of chicken cartilage for use in the present invention can be prepared from cartilage by a method usually used in this field.
For example, the hydrolyzed collagen type II can be obtained by treating the chicken cartilage with an enzyme. Specifically, the hydrolyzed collagen type II can be prepared by a pre-treatment step (1) in which chicken cartilage is heated in a liquid, and a step (2) in which the chicken cartilage after the pre-treatment step is treated with an enzyme. The enzyme for use in the step (2) is not limited as long as it is one usually used in this field. Examples include collagenase, papain, bromelain, actinidine, ficin, cathepsin, pepsin, chymosin, trypsin, protease, subtilisin, amino peptidase, endopeptidase and exopeptidase and enzyme preparations obtained by mixing these enzymes. The method of preparing hydrolyzed collagen type II is not limited to the enzyme treatment method. - The hydrolyzed collagen type II of chicken cartilage may be a solution obtained by hydrolysis of chicken cartilage, a concentrate or dry powder of the solution, or a purified product of the concentrate or dry powder. The purified product of the hydrolyzed collagen type II of chicken cartilage may be obtained by, for example, subjecting a solution obtained by hydrolysis of chicken cartilage to ultrafiltration, membrane treatment, liquid separation operation, or fraction treatment with resin or the like so as to increase the purity. After increasing the purity of the hydrolyzed collagen type II of chicken cartilage which contains at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, the purified product may be formed into powder by freeze-drying or spray-drying, for example.
- Hydrolyzed collagen type II of chicken cartilage is a peptide mixture that usually contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), and/or one or more salts thereof, and can be regarded as a collagen peptide derived from the collagen type II.
The weight average molecular weight of the hydrolyzed collagen type II of chicken cartilage is preferably 100 to 20,000, more preferably 2,000 to 8,000, still more preferably 3,000 to 7,000. The molecular weight and weight average molecular weight can be measured by Eurofins HPAEC-PAD method. - In an embodiment, one fraction or a combination of two or more fractions obtained by fractionation of hydrolyzed collagen type II of chicken cartilage by molecular weight by a method such as gel filtration can be used in the composition of the present invention.
The fraction obtained by fractionation of hydrolyzed collagen type II of chicken cartilage for use in the composition of the present invention is preferably the fraction 6 described above. In the present embodiment, fraction 6 and a fraction other than fraction 6 may be used in combination in the composition. - <Chicken extract>
The chicken extract (hereinafter sometimes referred to as "CE") for use in the present invention may be an extract that can be obtained by heating chicken meat used as a raw material in a liquid, or a commercial product. The raw material may contain bone, cartilage, legs, or the like, but preferably, the raw material does not contain the head or internal organs. - Examples of the commercial product of the chicken extract (CE) include "Brand's Essence of Chicken (BEC) (produced by Suntory Beverage & Food Asia Pte Ltd)", "ScotchTM Essence of Chicken (produced by Scotch Industrial (Thailand) Co., Ltd.)", "Quaker Essence of chicken (produced by Standard Foods Corporation (Taiwan) Co., Ltd.)", "Chicken stock and broth of SWANSONTM Produced by Campbell Soup Company (NYSE:CPB)", "Drip Chicken Essence produced by Eu Yan Sang International Ltd. (Singapore)", "Boned Chicken Tonic produced by Eu Yan Sang International Ltd. (Singapore)", "Boiled Essence of Chicken produced by Lao Xie Zhen Co. Ltd. (Taiwan)". Any of such commercial products may be used, but use of Brand's Essence of Chicken (BEC) is preferred.
- When producing chicken extract for use in the present invention by hot water extraction, the chicken extract can be produced by a method that is usually used in this field. For example, normal pressure extraction and/or pressurized extraction is performed using a liquid at a temperature of 100°C or higher, preferably 125°C or higher, and the resulting extract is treated with a membrane or filtered, whereby chicken extract can be produced. Specifically, the extract is obtained by a pre-treatment step (3) in which chicken meat is heated in a liquid, and a step (4) in which the liquid is replaced with a fresh liquid after the pre-treatment and the chicken meat is heated again. The heat treatment in each of the step (3) and the step (4) is preferably performed in a solvent. The solvent is preferably water, ethanol, or a mixture of these, for example.
The chicken extract encompasses a liquid extract obtained by the method described above; a diluted solution, concentrate, or dry powder of the liquid extract; and purified products of these. The purified products may be obtained by, for example, subjecting a chicken extract liquid to ultrafiltration, membrane treatment, liquid separation operation, or fraction treatment with resin or the like so as to increase the purity. After increasing the purity of the chicken extract, the purified product may be formed into powder by freeze-drying or spray-drying, for example. - Preferably, the chicken extract for use in the present invention contains carnosine and/or anserine and/or one or more salts thereof. Carnosine is β-alanyl・histidine, which is a dipeptide of β-alanine and histidine. Anserine is β-alanyl・1-methylhistidine in which histidine is methylated.
Examples of the carnosine salts and anserine salts include the same salts as those described above for Cyclo (Ala-Hyp), Cyclo (Pro-Gly), and tryptophan. - When the composition of the present invention contains carnosine and/or a salt thereof, for example, the amount of carnosine and/or a salt thereof in the composition is preferably 0.00001 wt% or more, more preferably 0.0001 wt% or more, and is preferably 10 wt% or less, more preferably 1 wt% or less in terms of carnosine. In an embodiment, for example, the amount of carnosine and/or a salt thereof in the composition is preferably 0.00001 to 10 wt%, more preferably 0.0001 to 1 wt% in terms of carnosine.
- When the composition of the present invention contains anserine and/or a salt thereof, for example, the amount of anserine and/or a salt thereof in the composition is preferably 0.00001 wt% or more, more preferably 0.0001 wt% or more, and also preferably 10 wt% or less, more preferably 1 wt% or less in terms of anserine. In an embodiment, for example, the amount of anserine and/or a salt thereof in the composition is preferably 0.00001 to 10 wt%, more preferably 0.0001 to 1 wt% in terms of anserine.
- Carnosine, anserine and salts thereof can be quantitated by HPLC, for example. More preferably, the food or beverage composition of the present invention contains carnosine and/or a salt thereof, and anserine and/or a salt thereof.
- Preferably, the weight ratio of the total weight of the carnosine, anserine and salts thereof in terms of carnosine and anserine to the total weight of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in terms of free form (total of carnosine and anserine/total in terms of free form) is 1/15000 to 200/1. The weight ratio is more preferably 1/200 to 200/1, still more preferably 1/50 to 50/1.
- In the expression "Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in terms of free from", a free form from Cyclo (Ala-Hyp) salt is Cyclo (Ala-Hyp), a free form from Cyclo (Pro-Gly) salt is Cyclo (Pro-Gly), a free form from guanosine salt is guanosine, and a free form from tryptophan salt is tryptophan.
- The weight ratio of the fraction 6 to the total of carnosine, anserine and salts thereof in terms of carnosine and anserine (fraction 6/total of carnosine and anserine) is preferably 1/100 to 10/1. The weight ratio is more preferably 1/100 to 5/1.
- The weight ratio of the hydrolyzed collagen type II of chicken cartilage (in terms of solids) to the total of carnosine, anserine and salts thereof in terms of carnosine and anserine (HCII/total of carnosine and anserine) is preferably 10000/1 to 10/1. The weight ratio is more preferably 1000/1 to 100/1.
- The amount of each component of the composition of the present invention is not limited, and can be set according to the form or the like of the composition.
In an embodiment, for example, the total amount of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in the composition of the present invention is preferably 0.01 wt% or more, more preferably 0.1 wt% or more, and preferably 99 wt% or less, more preferably 90 wt% or less. In an embodiment, for example, the total amount of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in the composition is preferably 0.01 to 99 wt%, more preferably 0.1 to 90 wt%. - In an embodiment, for example, the amount of fraction 6 in the composition of the present invention is preferably 0.01 wt% or more, more preferably 0.1 wt% or more, and preferably 99 wt% or less, more preferably 90 wt% or less. In an embodiment, for example, the amount of fraction 6 in the composition is preferably 0.01 to 99 wt%, more preferably 0.1 to 90 wt%. Herein, the amount of fraction 6 contains the amounts of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof.
- In an embodiment, for example, the amount of hydrolyzed collagen type II of chicken cartilage (in terms of solids) in the composition of the present invention is preferably 0.1 wt% or more, more preferably 0.5 wt% or more, and preferably 99 wt% or less, more preferably 90 wt% or less. In an embodiment, for example, the amount of hydrolyzed collagen type II of chicken cartilage (in terms of solids) in the composition is preferably 0.1 to 99 wt%, more preferably 0.5 to 90 wt%.
Herein, the amount of hydrolyzed collagen type II of chicken cartilage contains the amounts of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and fraction 6. - In an embodiment, for example, the amount of chicken extract (in terms of solids) in the composition of the present invention is preferably 0.1 wt% or more, more preferably 0.5 wt% or more, and preferably 99 wt% or less, more preferably 90 wt% or less. In an embodiment, the amount of chicken extract (in terms of solids) in the composition is preferably 0.1 to 99 wt%, more preferably 0.5 to 90 wt%. Herein, the amount of chicken extract (in terms of solids) contains the amounts of carnosine and anserine.
- Preferably, the composition of the present invention is used as a food, beverage, or medicine. Examples of the food or beverage include general foods or beverages, foods with function claims, health-promoting foods, foods for special dietary uses, dietary supplements, health supplements, and general supplements. The form of the food or beverage is not limited. For example, it may be a solid food or a liquid food. A beverage is preferred.
The form of the medicine is not limited. Non-limiting examples include preparations for internal administration such as capsules, tablets, powder, granules, and dry syrups; preparations for external administration such as ointment, adhesive skin patches, eye drops, and suppositories; and injections. The medicine is preferably a preparation for internal administration (oral medicine). - The composition of the present invention may contain pharmaceutically or dietary acceptable additives such as various carriers, excipients, diluents, acidulants, antioxidants, stabilizers, preservatives, flavouring or masking agents, emulsifiers, pigments, seasonings, pH adjusters, and nutritional enhancers.
- The composition of the present invention is applicable to both therapeutic use (medical use) and non-therapeutic use (non-medical use). The "non-therapeutic" is a concept that does not include medical activities, i.e., a concept that does not include methods of surgery, therapy or diagnosis of humans.
- <Anti-inflammatory composition>
In an embodiment, the composition of the present invention can be used to reduce inflammation. The composition of the present invention may be an anti-inflammatory composition. The composition may be an anti-inflammatory composition containing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract, as active components. - In order to achieve an anti-inflammatory effect contemplated by the present invention, at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract are added to a composition, in the same manner as described above for the above composition. The hydrolyzed collagen type II of chicken cartilage which contains at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract may be used directly, or a concentrate, dry powder, or purified product thereof may be added as described above, as long as the effect of the present invention is not impaired. The same additives as described above can be used. The same additives as described above can be used.
- Preferably, the composition of the present invention is orally fed (orally administered). The dose (which can also be described as "intake") of the composition of the present invention is not limited. The dose of the composition of the present invention may be suitably set according to the body weight of the subject and the like, as long as the inflammation reducing effect can be achieved.
- In an embodiment, when the composition of the present invention is orally fed or administered to a human (adult), the total dose of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in terms of free form is preferably 0.01 mg or more, more preferably 0.1 mg or more, and preferably 2000 mg or less, more preferably 1000 mg or less, per 60 kg body weight per day. In an embodiment, the total dose of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof in terms of free form to a human (adult) is preferably 0.01 to 2000 mg, more preferably 0.1 to 1000 mg, per 60 kg body weight per day.
- In an embodiment, when the composition of the present invention is orally fed or administered to a human (adult), the dose of fraction 6 is preferably 0.01 mg or more, more preferably 0.1 mg or more, and preferably 2000 mg or less, more preferably 1000 mg or less, per 60 kg body weight per day. In an embodiment, the dose of fraction 6 to a human (adult) is preferably 0.01 to 2000 mg, more preferably 0.1 to 1000 mg, per 60 kg body weight per day.
Herein, the dose of fraction 6 contains the amounts of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof. - In an embodiment, when the composition of the present invention is orally fed or administered to a human (adult), the dose of hydrolyzed collagen type II of chicken cartilage (in terms of solids) is preferably 0.01 mg or more, more preferably 0.1 mg or more, and also preferably 4000 mg or less, more preferably 3000 mg or less, per 60 kg body weight per day. In an embodiment, the dose of hydrolyzed collagen type II of chicken cartilage (in terms of solids) by a human (adult) is preferably 0.01 to 4000 mg, more preferably 0.1 to 3000 mg, per 60 kg body weight per day.
Herein, the dose of hydrolyzed collagen type II of chicken cartilage contains the amounts of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof or the amount of fraction 6. - In an embodiment, when the composition of the present invention is orally fed or administered to a human (adult), the dose of chicken extract (in terms of solids) is preferably 0.1 mg or more, more preferably 1 mg or more, and also preferably 15000 mg or less, more preferably 13000 mg or less, per 60 kg body weight per day. In an embodiment, the dose of chicken extract (in terms of solids) by a human (adult) is preferably 0.1 to 15000 mg, more preferably 1 to 13000 mg, per 60 kg body weight per day. The dose of chicken extract includes the amounts of carnosine, anserine and salts thereof.
- In an embodiment, when the composition of the present invention is orally fed or administered to a human (adult), the total dose of carnosine, anserine and salts thereof is preferably 0.001 mg or more, more preferably 0.01 mg or more, and also preferably 500 mg or less, more preferably 400 mg or less, per 60 kg body weight per day in terms of carnosine and anserine. In an embodiment, the total dose of carnosine, anserine and salts thereof fed to a human (adult) is preferably 0.001 to 500 mg, more preferably 0.01 to 400 mg, per 60 kg body weight per day in terms of carnosine and anserine.
- In an embodiment, the above amount of hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof and the above amount of chicken extract are preferably fed or administered at least once per day, for example, at once or in several times (e.g., two or three times) per day. In an embodiment, preferably, the above amount of hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof and the above amount of chicken extract are orally fed or administered to a human. In an embodiment, the composition of the present invention can be used to feed or administer the above amount of hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof and the above amount of chicken extract to a human, per 60 kg body weight per day.
- In an embodiment, when the composition of the present invention is fed to achieve the anti-inflammatory effect, preferably, the above amount of hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan and/or one or more salts thereof and the above amount of chicken extract are fed.
- The composition of the present invention inhibits the production of cytokines such as regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), and macrophage inflammatory protein-1 (MIP-1). The composition of the present invention is particularly highly effective in inhibiting the production of RANTES, MCP-1, IL-6, IL-8, IL-9 and MIP-1β.
Inflammation in a living body can be reduced by inhibiting the production of the above cytokines. - The composition of the present invention can be used to prevent or alleviate inflammatory conditions or diseases. The inflammatory conditions or diseases are, for example, conditions or diseases caused by inflammation or conditions or diseases accompanied by inflammation. Examples of such conditions or diseases include collagen diseases such as arthritis and rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, tendonitis, sciatica, intervertebral hernia, stenosis, myelopathy, back pain, facet joint pain, carpal tunnel syndrome, tarsal tunnel syndrome, post-lumbar surgery pain syndrome, AIDS, arteriosclerosis, asthma, arthritis, diabetes, hepatitis, stroke, dementia, muscle wasting, viral infection, skin aging including photoaging, cancer, aging, allergic diseases, Parkinson's disease, cerebral infarction, cataract, epilepsy, spinal cord injury, retinopathy of prematurity, nephropathy, peptic ulcer, pancreatitis, ulcerative colitis, myocardial infarction, adult respiratory distress syndrome, emphysema, vasculitis, edema, diabetes complications, UV damage, altitude sickness, porphyria, burns, frostbite, contact dermatitis, shock, multiple organ failure, DIC, fatigue, sarcopenia (muscle weakness), mitochondrial dysfunction, Alzheimer's disease, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and systemic lupus erythematosus (lupus). The composition of the present invention is preferably used to prevent or alleviate these diseases. In particular, the food or beverage composition is preferably used to prevent or alleviate diseases such as osteoarthritis, heumatoid arthritis and psoriatic arthritis.
Herein, prevention of conditions or diseases encompasses prevention of disease onset, delay of disease onset, reduction in disease incidence, reduction of risk of disease onset, and the like. Alleviation of conditions or diseases encompasses recovery of the subject from conditions or diseases, alleviation of conditions or disease symptoms, improvement of conditions or disease symptoms, delay or prevention of progress of conditions or diseases, and the like. - The subject to which the composition of the present invention is fed or administered (which can also be referred to as a "subject") is not limited. The subject is preferably a human or non-human mammal, more preferably a human.
In an embodiment, the subject may be one needing or wanting inhibition of inflammation. Such a subject may be, for example, one needing or wanting prevention or alleviation of inflammation or one needing or wanting prevention or alleviation of inflammatory conditions or diseases. In an embodiment, the subject in the present invention may be a middle-aged or older person. The composition of the present invention can also be used by a healthy person, for example, for the purpose of prevention of conditions that can be prevented or alleviated by reducing inflammation. - The composition of the present invention may be labeled with function claims stating that the effect is exerted by reducing inflammation. Such a label is also referred to as a label with function claims, the contents of the label are not limited. Examples of such function claims on the label include "relief of joint pain", "reduction of joint pain", "management of knee conditions", "maintenance of knee health", "improvement of joint health", ”improvement of joint mobility” and other function claims equivalent to those mentioned above.
In an embodiment of the present invention, the composition of the present invention is preferably a food or beverage labeled with the function claims described above, and a beverage is more preferred. The label may describe use of the composition of the present invention to achieve the above functions. The label may be added to the composition itself or a container or a package of the food or beverage composition. - <Production method>
The present invention also relates to a method of producing a composition, the method including mixing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, with chicken extract.
In the mixing, the Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof can be directly mixed with chicken extract. Yet, it is preferred to mix hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp) and the like with chicken extract to produce a composition. In this case, for example, a hydrolysate obtained by hydrolysis of collagen type II of chicken cartilage with an enzyme or the like can be directly used for mixing with the chicken extract. As described above, the fraction 6 derived from hydrolyzed collagen type II of chicken cartilage and containing Cyclo (Ala-Hyp) and the like may be added, or a concentrate, dry powder, or a purified product of hydrolyzed collagen type II of chicken cartilage may be added, as long as the effect of the present invention is not impaired. - In the production method of the present invention, the order of adding raw materials is not limited. For example, Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof, or the fraction 6 or hydrolyzed collagen type II of chicken cartilage which contains these components may be first placed in a container, followed by addition of chicken extract. Alternatively, chicken extract may be first placed in a container, followed by addition of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof, or the fraction 6 or hydrolyzed collagen type II of chicken cartilage which contains these components.
In the production method of the present invention, a preferred embodiment of the hydrolyzed collagen type II of chicken cartilage is as described above. A preferred embodiment of the chicken extract is as described above.
In the production method of the present invention, preferably, the chicken extract contains carnosine and/or anserine and/or one or more salts thereof. - In the production method of the present invention, commercially available chicken extract or chicken extract produced by hot water extraction can be directly mixed with Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof, or the fraction 6 or hydrolyzed collagen type II of chicken cartilage which contains these components. Yet, when the chicken extract is in the form of a concentrate, dry powder, or a purified product of the concentrate or the dry powder, the chicken extract may be diluted, dissolved, or the like in a liquid such as water, ethanol, or a mixture of water and ethanol, and then mixed with Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof, or the fraction 6 or hydrolyzed collagen type II of chicken cartilage which contains these components, for example. When the fraction 6 of hydrolyzed collagen type II of chicken cartilage which contains Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan and/or one or more salts thereof is in the form of a concentrate, dry powder, or a purified product thereof, such a product can be similarly diluted, dissolved, or the like in the liquid or the like before adding. Alternatively, such a product may be added without being diluted, dissolved, or the like in advance, and then blended with a liquid so as to be diluted, dissolved, or the like in the liquid.
- The composition produced in the production method of the present invention can contain the above-described additives, in addition to Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof as well as hydrolyzed collagen type II of chicken cartilage and chicken extract.
- The present invention also relates to use of at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract for the production of an anti-inflammatory composition.
Examples of the anti-inflammatory composition include a composition similar to the above-described composition containing Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof, and chicken extract. Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and/or one or more salts thereof can be used in the form of the fraction 6 or hydrolyzed collagen type II of chicken cartilage which contains these components. The same chicken extract and the same additives as described above can be used. - The present invention is more specifically described below with reference to examples. The present invention is not limited to these examples.
- Raw materials, reagents, and the like used in the following examples and comparative examples are as follows.
<Preparation of hydrolyzed collagen type II of chicken cartilage>
Fig. 1 shows a flow chart briefly describing a HCII preparation method. First, frozen chicken cartilage was thawed in water at 40°C, and cleansed in water at 40°C (1 hour). Next, the wash water was discarded, and fresh water was poured into a 1200L pot as to be 3 times amount to the chicken cartilage. The water was heated to the optimal working temperature for enzyme treatment, and the washed chicken cartilage was immersed therein to perform enzyme treatment for several hours. After the enzyme treatment, the pot containing the chicken cartilage was heated to 90°C or higher, and the temperature was held at 90°C or higher for 30 minutes, whereby the enzyme used in the earlier enzyme treatment was inactivated. The resulting mixture (the liquid and the enzyme-treated chicken cartilage) was filtered. The resulting liquid was concentrated. Lastly, the resulting concentrate was spray-dried at 200°C, whereby HCII powder was prepared. - <Measuring for the molecular weight of the HCII powder>
The molecular weight distribution of the HCII obtained was measured by Eurofins HPAEC-PAD method. Table 1 below shows the molecular weight distribution of the HCII obtained. The HCII obtained had a weight average molecular weight of 4582 which was obtained by calculating with usually used method in this field. -
- <Fractionation of HCII fractions>
(Material and method for HCII fractionation and bioactive identification)
(Materials)
Formic acid was purchased from Tokyo Chemical Industry Co. Ltd. Ultrapure water was obtained from Merck Milli-Q water purification system. - (Preparative Gel Permeation Chromatography (GPC))
Fractionation of HCII was carried out using a preparative VERITY 271 HPLC system (Gilson). HCII was dissolved in ultrapure water to prepare a 10 mg/mL (w/v) solution. After centrifugation at 14000 rpm for 5 min, 1000 μL aliquot was injected onto a preparative GPC column (BioSep 5 μm SEC-s2000 145Å LC column 300 × 21.2 mm (Phenomenex)) attached to a guard column (SecurityGuard PREP Cartridge C12 15 × 21.2 mm ID (Phenomenex)) and eluted isocratically with eluent A (ultrapure water: formic acid = 100 0.1 (v/v)) for 30 min at the rate of 5 mL/min. The chromatogram was observed at 214 nm.
Fractions were collected every 0.5 min between 8 min to 28 min using a GX series fraction collector (Gilson), the resulted 40 individual fractions were subsequently pooled into 7 fractions, P1 to P7 (P1: 8.5-12.0 min, P2: 12.0-13.5 min, P3: 13.5-14.5 min, P4: 14.5-16.0 min, P5: 16.0-17.5 min, P6: 17.5-19.0 min, P7: 19.0-27.5 min). The pooled fractions were evaporated to dryness in a freeze dryer (ScanVac) and the dried samples were stored at -20°C until further use. - In addition, Table 2 shows the molecular weights of the fractions obtained above. In Table 2, “Mw” and “Mp” indicate weight average molecular weight and peak molecular weight, respectively. As shown in Table 2, fraction 6 (P6) was composed of general small molecules having a molecular weight of less than 300.
The molecular weights of fractions of HCII were measured by HPLC Gel filtration method under the following conditions.
Instrument: Agilent 1100 Series
Detection: UV 214 nm
Flow rate: 1mL/min
Mobile phase: Isocratic 0.1 mM Sodium phosphate buffer at pH 6.8
Running time: 20 minutes
Column: BiosepTM 5μm SEC-s2000 145Å LC Column 300 x 7.8 mm -
- <Identification of main component of fraction P6>
Major components in fraction P6 were separated by Phenomenex, LunaTM Omega 5 μm PS C18 100A 250 × 4.6 mm on Agilent HPLC, 1100 series, eluted with eluent A (ultrapure water:formic acid = 100:0.1 (v/v)) and eluent B (acetonitrile:formic acid = 100:0.1 (v/v)), with the following linear gradient: 0-4.0 min: 100% eluent A; 4.0-12.0 min: 0-90% eluent A; 12.0-15.5 min: 90-80% eluent A; 15.5-17.0 min: 80-15% eluent A; 17.0-18.0 min: linear 15% eluent A; 18.0-19.0 min: 15-100% eluent A; and 19.0-21.0 min: 100% eluent A. The injection volume was 10 μL at the flow rate of 1 mL/min and UV absorbance of the eluents was monitored at 214 nm. The eluates were collected with equipped fraction collector. Four fractions were then freeze-dried and then reconstituted in purified water, which submitted to LC-MS analysis on an Agilent HPLC 1290 series-coupled TripleTOF 5600 (AB Sciex) with a Duo Spray Turbo V ion source and a gas generator (Peak Scientific). Some fractions were also submitted to proton-NMR experiment, conducted on Bruker ECA 400 for characterization. The identity of the major components in the fraction P6 was confirmed by commercially available chemicals.
Free amino acids in the fraction HCII were detected and quantified according to AOAC 999.13 method. - According to the results of the analysis, the major components in the fraction P6 were Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan.
- <Quantification of Cyclo (Ala-Hyp) and Cyclo (Pro-Gly)>
Cyclo (Ala-Hyp) was reconstituted in ultrapure water and injected onto a Zorbax Eclipse Plus C18 RRHD 1.8 μm 2.1 × 50 mm column (Agilent), with UHPLC Guard Zorbax Eclipse Plus C18 2.1 × 5 mm 1.8 μm (Agilent), and eluted with eluent A (ultrapure water:formic acid = 100:0.1 (v/v)) and eluent B (acetonitrile:formic acid = 100:0.1 (v/v)), with the following linear gradient: 0-0.5 min: 100% eluent A; 0.5-7.5 min: 100-65% eluent A; 7.5-10.0 min: 65-0% eluent A; 11.0-13.0 min: 0% eluent A; 13.0-13.1 min: 0-100% eluent A; and 13.1-15.0 min: 100% eluent A.
The injection volume was 10 μL at the flow rate of 300 μL/min and UV absorbance of the eluents was monitored at 214 nm. The collision energy (CE) and declustering potential (DP) of the MS were optimized as 27.0 V and 100 V respectively. Cyclo (Ala-Hyp) was detected using Q1/Q3 ion transitions at m/z 185.1/86.1 with the retention time of 2.45 min as quantifier and qualifier. A calibration curve was constructed by infusing 31.25 ng/mL, 62.5 ng/mL, 125 ng/mL, or 250 ng/mL of standard Cyclo (Ala-Hyp) into the mass spectrometer. The fraction P6 was reconstituted as 100 μg/mL solution as the working solution. The quantification of the Cyclo (Ala-Hyp) in the fraction P6 was done by Sciex OS (AB Sciex). - Cyclo (Pro-Gly) was reconstituted in ultrapure water and injected onto a Zorbax Eclipse Plus C18 RRHD 1.8 μm 2.1 × 50 mm column (Agilent), with UHPLC Guard Zorbax Eclipse Plus C18 2.1 × 5 mm 1.8 μm (Agilent), and eluted with eluent A (ultrapure water:formic acid = 100:0.1 (v/v)) and eluent B (acetonitrile:formic acid = 100:0.1 (v/v)), with the following linear gradient: 0-0.5 min: 100% eluent A; 0.5-7.5 min: 100-65% eluent A; 7.5-10.0 min: 65-0% eluent A; 11.0-13.0 min: 0% eluent A; 13.0-13.1 min: 0-100% eluent A; and 13.1-15.0 min: 100% eluent A.
The injection volume was 10 μL at the flow rate of 300 μL/min and UV absorbance of the eluents was monitored at 214 nm. The collision energy (CE) and declustering potential (DP) of the MS were optimized as 30.0 V and 100 V respectively. Cyclo (Pro-Gly) was detected using Q1/Q3 ion transitions at m/z 70.1/127.1 Th with the retention time of 2.6 min as quantifier and qualifier. A calibration curve was constructed by infusing 70 ng/mL, 140 ng/mL, 280 ng/mL, or 560 ng/mL of standard Cyclo (Pro-Gly) into the mass spectrometer. The fraction P6 was reconstituted as 100 μg/mL solution as the working solution. The quantification of the Cyclo (Pro-Gly) in the fraction P6 was done by Sciex OS (AB Sciex). - <Quantification of guanosine>
Guanosine was reconstituted in ultrapure water and injected onto a Zorbax Eclipse Plus C18 RRHD 1.8 μm 2.1 × 50 mm column (Agilent), with UHPLC Guard Zorbax Eclipse Plus C18 2.1 × 5 mm 1.8 μm (Agilent), and eluted with eluent A (ultrapure water:formic acid = 100:0.1 (v/v)) and eluent B (acetonitrile:formic acid = 100:0.1 (v/v)), with the following linear gradient: 0-0.5 min: 100% eluent A; 0.5-10.5 min: 100-0% eluent A; 10.5-14.0 min: 0% eluent A; 14.0-16.1 min: 0-100% eluent A; and 16.1-18.0 min: 100% eluent A. The injection volume was 10 μL at the flow rate of 300 μL/min and UV absorbance of the eluents was monitored at 214 nm. The collision energy (CE) and declustering potential (DP) of the MS were optimized as 10.0 V and 80 V respectively. Guanosine was detected using Q1/Q3 ion transitions at m/z152.1/284.1Th with the retention time of 2.17 min as quantifier and qualifier. A calibration curve was constructed by infusing 31.25 ng/mL, 62.5 ng/mL, 125 ng/mL, or 250 ng/mL of standard guanosine into the mass spectrometer. P6 was reconstituted as 100 μg/mL solution as the working solution. The quantification of the guanosine in P6 was done by Sciex OS (AB Sciex). - HCII contained 0.23wt% of Cyclo (Ala-Hyp), 0.30wt% of Cyclo (Pro-Gly), 0.10wt% of guanosine, and 0.132wt% of tryptophan, assuming the total weight of the HCII as 100 wt%.
- <Quantification of carnosine and anserine>
Quantification of carnosine and anserine in the chicken extract was performed by HPLC under the following conditions.
Carnosine standard stock was prepared by adding and dissolving carnosine powder in deionized water to a carnosine concentration of 2.50 mg/ml. Anserine standard stock was prepared by adding and dissolving L-anserine nitrate powder in deionized water to an L-anserine concentration of 3.96 mg/ml.
The weight of L-anserine was calculated by the following formula.
L-anserine (g) = 0.792 × L-anserine nitrate (g)
<Analysis conditions of HPLC>
Device: High performance liquid chromatography system with UV detector (Agilent 1100 produced by Agilent).
Column: Zorbax 300-SCX 4.6 mm ID × 250 mm (Agilent)
Mobile phase: 50 mM potassium dihydrogen phosphate
Flow rate: 1.0 mL/min
Flow channel: channel A (50 mM potassium dihydrogen phosphate), channel B (acetonitrile), channel D (deionized water)
UV detector wavelength: 210 nm
Sample injection volume: 10 μL - <Evaluation method of anti-inflammatory activity>
In Examples and Comparative Examples, the effect of inhibiting the production of inflammatory markers was evaluated by the following method.
(Raw materials and reagents)
Chicken extract (CE): Brand's Essence of Chicken (Suntory Beverage & Food Asia Pte Ltd, carnosine content in 1 ml: 0.94 mg/ml; anserine content in 1 ml: 1.9 mg/ml))
Chondrocyte medium (CM), fetal bovine serum (FBS), chondrocyte growth supplement (CGS), and penicillin/streptomycin (P/S): ScienCell Research Laboratories
IL-1β: R&D Systems
Poly-L-lysine (PLL) coated 96-well plates (Corning) - <Cell culture and pre-treatments>
Human chondrocytes (HC-a, ScienCell Research Laboratories) were isolated from human articular cartilage and were maintained in CM supplemented with 5% FBS, 1% CGS and 1% P/S. Cells were seeded in PLL-coated 96-well plate at a cell density of 4000 cells/well and incubated overnight at 37°C in a humidified gas chamber containing 5% CO2. The chondrocytes were washed once with PBS, and treated with chicken extract (CE), HCII, fraction P6 fractionated from HCII, a combination of the fraction P6 and CE, P6 compounds containing Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan, a combination of P6 compounds and CE, Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, or a combination of CE and any one of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine or tryptophan. After treating for 24 hours, the chondrocytes were further treated for 24 hours by adding 25 ng/m of IL-1β. The cells were centrifuged at 1100 g for 5 minutes and the supernatant was then used for cytokine analysis. For comparison, cells treated with IL-1β (IL-1β-treated cells) without being pre-treated with CE, HCII, fraction P6, P6 compounds, Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan were prepared. - (Multiplex cytokine analysis)
The Pro-Human Cytokine Multiplex Assays (Bio-Rad) was used to analyze the cytokines in the culture media. The following 27-plex analyses were performed: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, eotaxin (CCL11), macrophage colony-stimulating factor (M-CSF), interferon (IFN)-γ, monocyte chemotactic protein 1 (MCP-1; CCL2), macrophage inflammatory protein-1α (MIP-1α; CCL3), MIP-1β (CCL4), regulated on activation, normal T cell expressed and secreted (RANTES) (CCL5), TNF-α, and vascular endothelial growth factor (VEGF). Multiplex assays were carried out according to the manufacturers' instructions and run on the Luminex xPONENT for MAGPIX platform. Bio-Plex Manager version 6.0 was used for data processing. Cytokine and chemokine concentrations were calculated by reference to the standard curve. The sensitivity of the multiplex kit was < 5 pg/mL. - (Statistical analyses)
Statistical analysis was conducted using GraphPad Prism version 5.0 (GraphPad). All results were expressed as mean ± standard deviation. Statistical analysis was performed by analysis of variance (ANOVA) followed by posthoc Tukey's multiple comparison test. Data was considered to be significant when p < 0.05. - (Comparative Example 1) Effect of fraction P6 on inhibition of the production of inflammatory markers
To assess the influence of HCII and fraction P6 fractionated from HCII on the inflammatory markers (RANTES, MCP-1, IL-6, IL-8, IL-9, and MIP-1β) produced by the human chondrocytes, the following four different conditions were compared: cells before treatment (untreated control), IL-1β-treated cells, IL-1β + HCII-treated cells (Comparative Example 1), and IL-1β + fraction P6-treated cells (Comparative Example 1). HCII-treated cells and fraction P6-treated cells were pre-treated with HCII or fraction P6. In the pre-treatment, the HCII concentration was 5 mg/ml, and the fraction P6 concentration was 5 mg/ml.
As shown in Fig. 2, IL-1β 25 ng/mL induced inflammation in human chondrocytes leading to a significant increase in level of all the inflammatory markers as compared to untreated cells (control). Pre-treatment of the cells with HCII or the fraction P6 reduced the level of all the inflammatory markers induced by IL-1β. Data was represented as means ± SD (n = 3). * denotes significant difference with p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 against IL-1β (IL-1β-treated cells) unless otherwise indicated. - (Comparative Example 2) Effect of a combination of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan (P6 compounds) on inhibition of the production of inflammatory markers IL-6
To assess the influence of P6 compounds containing Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan (the ratio of these components were the same as in HCII) on the inflammatory marker IL-6 produced by the human chondrocytes, the following five different conditions were compared: cells before treatment (untreated control), IL-1β-treated cells, IL-1β + HCII-treated cells (Comparative Example 2), IL-1β + fraction P6-treated cells (Comparative Example 2) and IL-1β + P6 compounds-treated cells (Comparative Example 2). HCII-treated cells, fraction P6-treated cells and P6 compounds-treated cells were pre-treated with HCII, fraction P6 or P6 compounds. In the pre-treatment, the HCII concentration was 5 mg/ml, the fraction P6 concentration was 5 mg/ml and the P6 compounds concentration was 100 mg/ml.
As shown in Fig. 3, IL-1β 25 ng/mL induced inflammation in human chondrocytes leading to a significant increase in level of IL-6 as compared to untreated cells (control). Pre-treatment of the cells with HCII, P6, or P6 compounds reduced the level of the inflammatory marker IL-6 induced by IL-1β. Data was represented as means ± SD (n = 3). * denotes significant difference with p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 against IL-1β. - (Comparative Example 3) Effect of Cyclo (Pro-Gly) and a combination of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan (P6 compounds) on inhibition of the production of inflammatory markers MCP-1(MCAF)
To assess the influence of P6 compounds containing Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, and tryptophan (the ratio of these components were the same as in HCII) and Cyclo (Pro-Gly) (cPG) on the inflammatory marker MCP-1(MCAF) produced by the human chondrocytes, the following six different conditions were compared: cells before treatment (untreated control), IL-1β-treated cells, IL-1β + HCII-treated cells (Comparative Example 3), IL-1β + fraction P6-treated cells (Comparative Example 3), IL-1β + P6 compounds-treated cells (Comparative Example 3) and IL-1β + cPG compounds-treated cells (Comparative Example 3). HCII-treated cells, fraction P6-treated cells, P6 compounds-treated cells and cPG-treated cells were pre-treated with HCII, fraction P6, P6 compounds or cPG. In the pre-treatment, the HCII concentration was 5 mg/ml, the fraction P6 concentration was 5 mg/ml, the P6 compounds concentration was 100 mg/ml and the cPG concentration was 50 mg/ml, 100 mg/ml or 250 mg/ml.
As shown in Fig. 4, IL-1β 25 ng/mL induced inflammation in human chondrocytes leading to a significant increase in level of MCP-1(MCAF) as compared to untreated cells (control). Pre-treatment of the cells with HCII, P6, Cyclo (Pro-Gly) or P6 compounds reduced the level of the inflammatory marker MCP-1(MCAF) induced by IL-1β. Data was represented as means ± SD (n = 3). * denotes significant difference with p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 against IL-1β. - <Example 1> Synergistic effect of combination of HCII and CE
To assess a synergistic effect of a combination of HCII and CE on inhibition of the production of an inflammatory marker MIP-1β, pre-treatment was performed with HCII alone, CE alone, or a combination of HCII and CE. In the pre-treatment, the HCII concentration was 0.5 mg/ml and the CE concentration was 1.25 mg/ml.
As shown in Fig. 5, a combination of HCII 0.5 mg/mL and CE 1.25 mg/mL provided a synergistic effect of reducing inflammation, as compared to treatment with HCII or CE alone. Data is represented as means ± SD (n = 3). * denotes significant difference with p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 against IL-1β (IL-1β-treated cells) unless otherwise indicated. - <Example 2> Synergistic effect of combination of HCII and CE and a synergistic effect of a combination of fraction P6 and CE on inhibition of the production of inflammatory markers MCP-1 and MIP-1β
To assess a synergistic effect of a combination of HCII and CE and a synergistic effect of a combination of fraction P6 and CE on inhibition of the production of inflammatory markers MCP-1 and MIP-1β, pre-treatment was performed with IL-1β and HCII alone, CE alone, P6 alone, a combination of HCII and CE, or a combination of P6 and CE as in Example 1. In the pre-treatment, HCII concentration was 2.5mg/mL or 5mg/mL, P6 concentration was 2.5 mg/ml or 5mg/mL, and the CE concentration was 6.25 mg/ml.
Fig. 6(a) and Fig. 6(b) show the results. Data is represented as means ± SD (n=3). * denotes significant difference with p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 against IL-1β (IL-1β-treated cells) unless otherwise indicated. - <Example 3> Synergistic effect of combination of HCII and CE, a combination of P6 compound and CE, a combination of Cyclo(Pro-Gly) and CE, a combination of Cyclo (Ala-Hyp) and CE, a combination of guanosine and CE, and a combination of tryptophan and CE on inhibition of the production of inflammatory markers
To assess a synergistic effect of a combination of HCII and CE, a combination of P6 compound and CE, a combination of Cyclo(Pro-Gly)(cPG) and CE, a combination of Cyclo (Ala-Hyp) (cAH) and CE, a combination of guanosine and CE, and a combination of tryptophan and CE on inhibition of the production of inflammatory markers IL-6, IL-8, IL-9, MCP-1, MIP-1β and RANTES, pre-treatment was performed as in Example 1. In the pre-treatment, HCII concentration was 2.5mg/mL, P6 compounds concentration was 25 mg/ml, 125 mg/ml or 250mg/mL, cPG concentration was 25 mg/ml, 125 mg/ml or 250mg/mL, cAH concentration was 25 mg/ml, 125 mg/ml or 250mg/mL, guanosine concentration was 25 mg/ml, 125 mg/ml or 250mg/mL, tryptophan concentration was 25 mg/ml, 125 mg/ml or 250mg/mL, and CE concentration was 6.25 mg/ml.
Fig. 7-1(a), Fig. 7-1(b), Fig. 7-2(c), Fig. 7-2(d), Fig. 7-3(e) and Fig. 7-3(f) show the results. Data is represented as means ± SD (n = 3). * denotes significant difference with p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 against IL-1β (IL-1β-treated cells) unless otherwise indicated. - <Example 4> A Randomized, Double-blind, Four-arm Pilot Study to Evaluate the Effects of HCII and CE on knee pain
This pilot study was carried out in a single-center, and as double-blind, randomized, placebo-controlled study. - (Subject enrolment and randomization)
A total of 160 subjects between the ages of 45 to 75 were selected using inclusion and exclusion criteria summarized in Table 3. Subjects were randomly assigned to four groups i.e. “Placebo”, “Glucosamine”, “HCII” and “HCII and CE”. Each group included 40 subjects. -
- (Investigational product)
“Placebo” group took a mixture of 6.8g of maltodextrin and 7mg of xanthan gum.
“Glucosamine” group took 1.5g of glucosamine hydrochloride. Glucosamine hydrochloride acted as an active comparator.
“HCII” group took BRAND’S Collagen Hydrolysate (Suntory Beverage & Food Asia Pte Ltd), a hydrolyzed chicken sternal cartilage extract composed of a naturally occurring matrix of hydrolyzed collagen type II (HCII) and low molecular weight chondroitin sulfate and hyaluronic acid (HA). This product included HCII containing Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine and tryptophan. Each bottle with a volume of 68mL contained 2g of HCII providing naturally occurring composition of HCII (66.5%), depolymerized chondroitin sulfate (18%) and HA (11%). Uncharacterized components of sternal cartilage account for the remaining 4.5%.
“HCII and CE” group took a mixture of 70g of BRAND’S Essence of chicken (BEC) (dry weight: 5-6g) and 2g of HCII in 68mL.All test products were prepared as liquid products in glass bottles, which were isocaloric, identical in appearance and equivalent in flavour and texture. The participants had to take the investigational product once daily in the morning after meal.
Subjects were allowed to continue on concomitant medication or supplements deemed not to affect the outcome of the study. Analgesics or painkillers were allowed as a rescue medication under prescription. Proportion of days covered (PDC) of painkillers was calculated based on the records in the Concomitant Medication of Painkiller section and defined as the percentage of painkillers covered days over the total number of days in the interval between visits. Any treatment or dietary supplement that could support joint, bone and muscle health including hormone therapy (growth hormone, progesterone, estrogen, or testosterone), calcium and vitamin D, supplements enriched with amino acids, peptides, proteins, omega-3, omega-6, glucosamine or chondroitin were prohibited throughout the study duration. - (Procedure)
The study consisted of a screening visit (28 days before baseline visit), followed by a baseline visit (Baseline visit was Day 0. Screening and baseline visits can be on the same day), and 3 follow-up visits (Week 8, 16, and 24). Subjects were screened from Day -28 to Day 0 to determine the eligibility for the study. Intake of test product was taken starting from the day following the baseline visit for 168 days (24 weeks) consecutively. For 168 days (24 weeks) consecutively, subjects took one bottle of test product daily in the morning (after meal). Intake compliance was recorded on a diary card.
The visual analogue scale (VAS) of knee pain was scored at Day 0, Day 7 and Day 14 post-intake.
During the study period, subjects were recommended to do the resistance training (not mandatory) twice a week at home, 30 minutes each time following the training schedule. Training was recorded on a diary card. Food dietary in the prior week before visits was recorded using a food questionnaire. - (Treatment compliance)
Compliance, regarding the intake of the investigational product, was checked by the collection of unused products and the daily records of the consumption kept by the subjects. Compliance was defined by the percentage of assigned doses that were actually consumed over number of days between visits. A 70% of consumption was considered as compliant. - (Exercise programme)
All subjects were encouraged to do the resistance training for 30 minutes twice a week at home following the training manual provided at baseline visit. Compliance on the training programme were recorded on a diary card and were calculated using the following formula: -
- A compliance rate of ≧ 50% was considered as compliant.
- (Visual Analogue scale (VAS) of knee pain)
The visual analogue scale (VAS) was scored from 0 to 100 mm, where 0 indicates no pain and 100 the worst pain ever. At Day 0, Day 7 and Day 14 post-intake, respondents were asked to specify the level of pain felt by indicating a position along a continuous line by drawing a straight line on the scale. - (Tolerability and safety)
Spontaneous reported adverse events were recorded throughout the study. Vital signs were monitored at every visit. For assessment of safety of the investigational products, serum and urine of all participants were evaluated at each visit of the study duration. - (Statistical analyses)
Per-protocol statistical analyses were performed, according to the a priori statistical analysis plan. Randomized subjects with intake compliance rate ≧ 70% were included in the per-protocol analyses. Analyses of safety parameters were performed based on the subjects who have taken at least 28 bottles of the study product. Dichotomous variables were reported using percentages, whereas continuous variables were reported as mean and SD. Comparisons of categorical variables were performed with chi-square test, whereas the Kruskal-Wallis test was used to compare differences between groups for continuous variables.
Repeated measures analysis of variance (ANOVA) was performed using mixed-effect models used for testing mean difference in changes between the study groups, with the intake-by-visit interaction as fixed effect factors, for continuous primary and secondary endpoints. All results were considered to be statistically significant if the corresponding p-value was below 0.05. If the intake-by-visit interaction term was significant, post-hoc, pairwise comparisons between treatment groups were performed and adjusted p-values reported. Variables which were expected to influence endpoints were included in the models as factors. Gender and gender*visit interaction term was included as a factor in joint health analysis.
In addition, subgroup analysis was done for subjects doing resistance training less than 10th percentile of the total training period. An independent statistician performed the analyses using SAS version 9.4 (Cary, USA). - <Results>
(Baseline characteristics and treatment compliance)
A total of 160 subjects were enrolled and 151 subjects completed the study and were included in the statistical analysis (PP). Nine subjects dropped out during the study; there were no significant differences in the number of the drop-outs between the groups. None of the drop-outs were related to any side effects caused by the intake of the investigational products or placebo. No adverse events were noted. No clinically significant changes were observed in the serum biochemistry markers and urinalysis.
Overall, there was no statistically difference in the compliance rate between all four groups (Table 4). To evaluate the homogeneity of the data, all parameters were compared between four arms. There was no statistically significant difference between the study groups at baseline (Table 4). -
- (Changes in VAS of knee pain)
After 14 days of intake, sub-group analysis for subjects doing less than 10th percentile of total resistance training period showed that placebo group experienced significantly increased pain score of 200% from baseline at Day 14 compared to HCII+CE (p=0.047) group, with and 42.9% from Day 0(Fig. 8, Table 5).
In Table 5, “P-value ($)” means p value between groups; “(a)” denotes method used to determine the p value((a)= One-way ANOVA); “95%C.I.” denotes 95% Confidence Interval.
In Fig. 8, two numerical values in parentheses for each data are “mean - standard deviation” and “mean + standard deviation”. -
- (Conclusion)
In conclusion, HCII and CE were well-tolerated and provided a quick and significant symptomatic relief in patients suffering from osteoarthritic pain. Compared to placebo, combination of HCII and CE significantly reduced knee joint pain in just 14 days in subjects who did minimal amount of resistance training.
In vitro studies suggest that mechanism of action may be through modification of underlying disease processes, particularly inhibition of inflammation that leads to localized pain sensation. Taken together, a combination of HCII and CE may be considered as a safe and efficacious complement to current medical and dietary options in the management of OA symptoms. - The present invention can provide a novel composition containing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract. The composition of the present invention can be used as a food or beverage composition or a pharmaceutical composition to reduce inflammation and joint pain. Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, salts thereof, and chicken extract can be consumed as foods, beverages, or the like, and are also advantageous in terms of high safety.
Claims (13)
- A composition comprising:
at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof; and
chicken extract. - The composition according to claim 1,
wherein the total amount of the at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof is 0.01 to 99 wt%. - The composition according to claim 1 or 2,
wherein the composition contains a component derived from hydrolyzed collagen type II of chicken cartilage and having a molecular weight of less than 1100 and weight average molecular weight of 150 to 250 as determined by HPLC gel filtration. - The composition according to any one of claims 1 to 3,
wherein the composition contains hydrolyzed collagen type II of chicken cartilage. - The composition according to any one of claims 1 to 4,
wherein the chicken extract contains carnosine and/or anserine and/or one or more salts thereof. - The composition according to any one of claims 1 to 5,
wherein the composition is a food, beverage, or medicine. - The composition according to any one of claims 1 to 6,
wherein the composition is used to reduce inflammation. - The composition according to any one of claims 1 to 7,
wherein the composition inhibits the production of at least one cytokine selected from the group consisting of regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), and macrophage inflammatory protein-1 (MIP-1). - The composition according to any one of claims 1 to 8,
wherein the composition is used to prevent or alleviate inflammatory conditions or diseases. - A method of producing a composition, comprising:
mixing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof with chicken extract. - The method according to claim 10,
wherein the mixing includes mixing hydrolyzed collagen type II of chicken cartilage with chicken extract, the hydrolyzed collagen type II containing at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof. - The method according to claim 10 or 11,
wherein the chicken extract contains carnosine and/or anserine and/or one or more salts thereof. - Use of at least one selected from the group consisting of Cyclo (Ala-Hyp), Cyclo (Pro-Gly), guanosine, tryptophan, and salts thereof, and chicken extract for the production of an anti-inflammatory composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201913617Y | 2019-12-27 | ||
PCT/JP2020/025296 WO2021131106A1 (en) | 2019-12-27 | 2020-06-26 | Composition containing cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract, production method thereof, and use of cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4081303A1 true EP4081303A1 (en) | 2022-11-02 |
EP4081303A4 EP4081303A4 (en) | 2024-01-24 |
Family
ID=76573241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20906765.1A Pending EP4081303A4 (en) | 2019-12-27 | 2020-06-26 | Composition containing cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract, production method thereof, and use of cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4081303A4 (en) |
JP (1) | JP2023508934A (en) |
CN (1) | CN115066273A (en) |
AU (1) | AU2020412909A1 (en) |
TW (1) | TW202123958A (en) |
WO (1) | WO2021131106A1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003048850A (en) * | 2001-06-01 | 2003-02-21 | Nippon Meat Packers Inc | Therapeutic agent of arthropathy, and functional food |
RU2255758C2 (en) * | 2003-09-18 | 2005-07-10 | Закрытое акционерное общество "Научно-производственное объединение "ТЕХКОН" | Biologically active carnosine-anserine-containing complex and method for its preparing |
FR2900155B1 (en) * | 2006-04-21 | 2008-06-27 | Diana Naturals Sa | AVIAN CARTILAGE HYDROLISATE, PROCESS FOR OBTAINING AND USES |
JP2009102248A (en) * | 2007-10-22 | 2009-05-14 | Lytone Enterpprise Inc | Pharmaceutical composition for rapidly decreasing uric acid in blood and package, and use of anserine for rapidly decreasing uric acid in blood |
CN101999622A (en) * | 2009-09-01 | 2011-04-06 | 上海太太乐食品有限公司 | Liquid compound seasoning and preparation method thereof |
JP2015193582A (en) * | 2014-03-28 | 2015-11-05 | 国立大学法人 東京大学 | Agent containing imidazoledipeptide |
JP2020532295A (en) * | 2017-08-31 | 2020-11-12 | ロンザ,エルエルシー | How to use health promotion compositions and supplements |
RU2694718C1 (en) * | 2018-07-16 | 2019-07-16 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт пушного звероводства и кролиководства имени В.А. Афанасьева" (ФГБНУ НИИПЗК) | Complete feedstuff and method of its use in feeding slaughtering young minks |
-
2020
- 2020-06-26 WO PCT/JP2020/025296 patent/WO2021131106A1/en unknown
- 2020-06-26 EP EP20906765.1A patent/EP4081303A4/en active Pending
- 2020-06-26 CN CN202080090134.0A patent/CN115066273A/en active Pending
- 2020-06-26 AU AU2020412909A patent/AU2020412909A1/en active Pending
- 2020-06-26 JP JP2022538443A patent/JP2023508934A/en active Pending
- 2020-06-29 TW TW109121867A patent/TW202123958A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202123958A (en) | 2021-07-01 |
JP2023508934A (en) | 2023-03-06 |
EP4081303A4 (en) | 2024-01-24 |
CN115066273A (en) | 2022-09-16 |
AU2020412909A1 (en) | 2022-07-14 |
WO2021131106A1 (en) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102204299B1 (en) | Therapeutic agent for coronavirus comprising Elaeocarpus sylvestris extract as effective component | |
US20110135721A1 (en) | Preparations with rosehip extracts, and method of producing rosehip extracts | |
WO2019246221A1 (en) | Compositions and methods for the treatment of liver diseases and disorders | |
JPWO2002034257A1 (en) | Central nervous system fatigue recovery or prevention agent and food for fatigue recovery or prevention | |
KR20180117259A (en) | Peptides having anti-inflammatory activity and composition the same for anti-inflammatory | |
CN111632130B (en) | Application of milk-derived active peptide CCL-3S in preparation of sleep-promoting product | |
WO2018021471A1 (en) | Food composition for improving brain function | |
Du et al. | Interactions between adenosine receptors and cordycepin (3'-deoxyadenosine) from cordyceps militaris: possible pharmacological mechanisms for protection of the brain and the amelioration of covid-19 pneumonia | |
WO2021131106A1 (en) | Composition containing cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract, production method thereof, and use of cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract | |
WO2021131104A1 (en) | Composition containing peptide, production method thereof, and use of peptide | |
JP6671671B1 (en) | Preventive and / or therapeutic drug for allergic rhinitis | |
KR102507470B1 (en) | Pharmaceutical composition for the prevention or treatment of allergic diseases containing Streptococcus pyogenes dead cells or SpeA protein | |
KR102032945B1 (en) | Peptides having anti-inflammatory activity and composition the same for anti-inflammatory | |
WO2021131105A1 (en) | Food or beverage composition containing peptide and/or salt thereof, production method thereof, use of hydrolyzed collagen type ii, composition for inhibiting bone resorption, and use of chicken extract | |
KR101830395B1 (en) | Composition comprising squalene for enhancement of muscle function and prevention of muscle damage | |
KR101991880B1 (en) | Composition for treating or preventing hypertension | |
EP3669870A1 (en) | Use of carnosol for increasing muscle protein synthesis | |
JP6708376B2 (en) | IFN-γ and/or IL-17 production inhibitor, and Th1 cell and/or Th17 cell differentiation inhibitor | |
TW201125573A (en) | Glucagon-like peptide-1 secretion promoter | |
KR102227723B1 (en) | Composition for preventing or treating of skin diseases comprising 2-amino-2-norbornane carboxylic acid | |
KR20240032246A (en) | Immune enhancing composition containing phosvitin phosphopeptide and method for preparing the same | |
TW202333756A (en) | Placental composition | |
Alhindi | Anti-Diabetic and Antihyperlipidemic Potential of Combined Melatonin and Garlic in Nicotinamide-Streptozotocin Induced Diabetic Mice | |
Rudziński et al. | Hair loss following COVID-19 infection-the state of current knowledge and treatment approaches. | |
Du et al. | Jian Y ang, Hongxiao Jia, Interactions Between Adenosine Receptors and Cordycepin (3'-Deoxyadenosine) from Cordyceps Militaris: Possible Pharmacological Mechanisms for Protection of the Brain and the Amelioration of Covid-19 Pneumonia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220715 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240103 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/708 20060101ALI20231220BHEP Ipc: A61K 31/405 20060101ALI20231220BHEP Ipc: A61K 38/12 20060101ALI20231220BHEP Ipc: A23L 33/18 20160101ALI20231220BHEP Ipc: A23L 33/175 20160101ALI20231220BHEP Ipc: A23L 33/10 20160101ALI20231220BHEP Ipc: A61P 29/00 20060101AFI20231220BHEP |